🏷

Classifications

IUIS Category

👪

Inheritance

1

Autosomal dominant, usually de novo HP:0000006

Heterozygous TINF2 variants, dominant in mechanism but almost never inherited: every genetically characterised Revesz patient reported so far has arisen de novo from unaffected parents. That is a consequence of the disease rather than a property of the gene - children who die before six do not reproduce - and it distinguishes this presentation from TINF2 dyskeratosis congenita generally, which is transmitted through families. No de_novo_rate is recorded. Only twelve of the eighteen assembled patients were genotyped, parental testing is not documented for all of them, and a percentage computed on that basis would give a precision the source does not have.

Autosomal dominant inheritance

Show evidence (4 references)

PMID:33097095 SUPPORT Human Clinical

"In contrast to classical DKC, all cases of RS represented de novo mutations with unaffected parents, reflecting the severe course and early death in this disease."

The de novo observation and the review's own explanation of why it follows from the severity rather than from the gene.

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

The mode of inheritance the expert panel curated the gene under.

PMID:20301779 SUPPORT Other

"Autosomal dominant: NAF1, RPA1, TERC, TINF2, and ZCCHC8."

GeneReviews assigns TINF2 to autosomal dominant transmission within the DC/TBD gene set, which is the mode this entry records.

+ 1 more reference

◈

Mechanistic Hypotheses

2

DC-cluster TIN2 variants shorten telomeres by impairing telomerase recruitment

tin2_telomerase_recruitment_defect ALTERNATIVE

Evidence balance 2 support

Ectopically expressed TIN2 carrying dyskeratosis congenita missense mutations shortens telomeres in human cells, and the mutants are specifically defective in associating with the telomerase RNA component and with telomerase activity, while leaving total cellular telomerase activity, TIN2 localisation and telomere end protection intact. On this account the lesion is a failure to deliver telomerase to the telomere through TPP1, not a failure of the enzyme or of end protection. This is the more widely cited of the two models and fits the clinical observation that telomerase RNA levels are normal in TINF2 patients. It is nevertheless recorded as ALTERNATIVE rather than CANONICAL, because the mouse work below shows the defect is not solely telomerase-dependent, and no experiment has apportioned the two.

Pathograph links

Impaired Shelterin-Mediated Telomere Maintenance -> Extreme Telomere Shortening DIRECT Under the recruitment model, the DC-cluster variant reduces TPP1-dependent delivery of telomerase to the telomere, so telomeres are not replenished and shorten with every division.

Show evidence (2 references)

PMID:21536674 SUPPORT In Vitro

"we found TIN2 to participate in the TPP1-dependent recruitment of telomerase activity. Furthermore, DC mutations in TIN2 led to its decreased ability to associate with TERC and telomerase activity."

The core result of this model: DC-cluster TIN2 mutants lose telomerase association, in a pathway TIN2 normally supports through TPP1.

PMID:21536674 SUPPORT In Vitro

"However, this telomere shortening was not accompanied by changes in total telomerase activity, localization of TIN2, or telomere end protection status."

The controls that make this a recruitment defect specifically rather than a general loss of telomerase or of shelterin function.

DC-cluster TIN2 variants shorten telomeres by a telomerase-independent replication defect

tin2_telomere_replication_defect ALTERNATIVE

Evidence balance 2 support

A knock-in mouse carrying the equivalent of the TIN2 K280E dyskeratosis congenita allele shortens telomeres faster than controls even when telomerase RNA is deleted entirely, which is a result the recruitment model cannot produce: if the only defect were telomerase delivery, removing telomerase from both genotypes should abolish the difference. The same allele induces ATR signalling and a fragile-telomere phenotype, the signature of a replication problem at telomeric DNA. The authors' own reading is that the two mechanisms compose - a replication defect in telomerase-negative somatic tissue on top of impaired telomerase action in stem cell compartments - which if correct would explain why so many different tissues fail. Recorded as ALTERNATIVE alongside the recruitment model rather than in place of it.

Pathograph links

Impaired Shelterin-Mediated Telomere Maintenance -> Extreme Telomere Shortening DIRECT Under the replication model, the DC-cluster variant makes the telomere a fragile replication substrate, producing attrition that persists in the complete absence of telomerase.

Show evidence (2 references)

PMID:24449270 SUPPORT Model Organism

"Unexpectedly, telomere shortening was accelerated in TIN2(+/DC) mTR(-/-) mice and MEFs compared with TIN2(+/+) mTR(-/-) controls, establishing that the TIN2(DC) telomere maintenance defect was not solely due to diminished telomerase action."

The decisive experiment: the shortening persists and is accelerated with telomerase RNA deleted, so it cannot be entirely a telomerase-recruitment failure.

PMID:24449270 SUPPORT Model Organism

"The TIN2(DC) allele induced mild ATR kinase signaling at telomeres and a fragile telomere phenotype, suggestive of telomere replication problems."

The mechanistic signature the authors propose for the telomerase-independent component.

?

Discussions and Knowledge Gaps

4

Is Revesz syndrome a disease, or a severity band on TINF2 dyskeratosis congenita that two authorities have already voted to retire?

CONTROVERSY OPEN revesz_is_a_severity_band_not_a_disease

Attached to

disease#Revesz Syndrome phenotypes#Bilateral Exudative Retinopathy genetic#TINF2

The case for retiring the eponym is strong and comes from two independent directions. ClinGen's Interstitial Lung Disease Gene Curation Expert Panel applied the Lumping and Splitting Working Group criteria in 2024 and merged Revesz syndrome into TINF2-related short telomere syndrome, finding no difference in molecular mechanism or inheritance from classical dyskeratosis congenita. Independently, a 2026 widefield angiography series found retinovascular abnormality in every eye of every telomere biology disorder patient examined, most of them asymptomatic, and proposed replacing the eponym with Short Telomere Associated Retinopathy. Add the Karremann review's finding that genotype cannot define the syndrome, and the entity has no mechanistic, genetic or now even phenotypic boundary. The case for keeping a record is narrower but real. The natural history is categorically different - median survival 6.5 years against survival into adulthood in classical dyskeratosis congenita - and the retinal and cerebral branches of the pathograph are absent from the dismech Dyskeratosis Congenita entry, whose subtype list is keyed by gene and whose Subtype records cannot hold pathophysiology in any case. MONDO, OMIM and Orphanet all still carry the term, so a clinician or a pipeline will keep encountering it. This entry takes the position that curating the concept with the dispute attached is more useful than deleting it: a reader who arrives at MONDO:0009990 should find the lumping decision and the STAR proposal, not silence. If dismech later curates TINF2-related short telomere syndrome as an entity, this file should be reconsidered as a subtype of it.

Show evidence (4 references)

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z REFUTE Other

"Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism or inheritance pattern between these conditions suggesting that these may constitute a disease spectrum associated with variants in TINF2 ."

The formal, criteria-based decision against Revesz syndrome being a separate entity. REFUTE relative to the claim that this is a distinct disease.

PMID:42617951 REFUTE Human Clinical

"Patients with retinopathy have been termed Revesz syndrome until now, but with the advent of WF-FA, we show that the retinopathy is likely more prevalent than previously thought."

The ophthalmological argument against the eponym: the feature that defines it is not distinctive once imaged properly.

PMID:42617951 REFUTE Human Clinical

"We propose that these findings be termed Short Telomere Associated Retinopathy (STAR) to reflect the underlying systemic pathophysiology."

The proposed replacement terminology, named here so the concept is findable under both.

+ 1 more reference

Why do the retina and the cerebral microvasculature fail catastrophically in these children when other carriers of the identical TINF2 variant develop classical dyskeratosis congenita?

KNOWLEDGE GAP OPEN revesz_tissue_selectivity_gap

Attached to

pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy pathophysiology#Intracranial Calcification and Cerebrovascular Fragility pathophysiology#TINF2 Exon 6 Cluster Variant

This is the central unexplained fact of the disease. R282H appears in unrelated probands with classical dyskeratosis congenita, with Revesz syndrome, and with overlapping presentations, and the review that assembled the cohort states that genotype alone cannot define the syndrome. Something other than the TINF2 allele determines whether a child develops sight-destroying retinopathy and intracranial calcification in infancy. No candidate has been tested. Parentally inherited telomere length, a modifier locus, a second variant, and stochastic variation in how short telomeres are at conception are all plausible and none has been examined in a Revesz cohort - which, at eighteen patients across the whole literature, may be too small to examine any of them. The STAR finding partially dissolves the question for the retina by making retinopathy universal, but it does not touch the CNS branch, and it does not explain the difference in severity and age of onset.

Proposed experiments

Parental telomere-length and modifier analysis across TINF2 carriers stratified by ocular phenotype

revesz_modifier_and_telomere_setpoint

Assemble TINF2 exon-6 carriers with and without early exudative retinopathy, measure telomere length in the probands and both parents, and sequence for modifier variants in telomere-maintenance and retinal-vascular genes. The design tests whether the Revesz phenotype tracks a shorter inherited telomere set point rather than a distinct lesion.

Would support

pathophysiology#Extreme Telomere Shortening

Would refute

pathophysiology#Extreme Telomere Shortening

Supporting outcome

Carriers with the Revesz phenotype have shorter telomeres, or shorter parental telomeres, than genotype-matched carriers without it, in a dose-dependent relation to age of ocular onset.

Refuting outcome

Telomere length is indistinguishable between carriers with and without the Revesz phenotype, which would place the determinant outside telomere length altogether.

Senescence and telomere phenotyping of retinal microvascular endothelium in telomere biology disorders

revesz_retinal_endothelial_senescence

Measure telomere length and senescence markers in retinal microvascular endothelial cells - from donor eyes, or from patient iPSC-derived retinal microvascular endothelium - and compare against a matched non-retinal endothelial bed, to test whether the retinal periphery is intrinsically more vulnerable to short telomeres than other vascular beds.

Would support

pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy

Would refute

pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy

Supporting outcome

Retinal microvascular endothelium shows shorter telomeres and higher senescence-marker burden than the comparator bed in the same patients, with peripheral retina worse than posterior pole.

Refuting outcome

No difference in telomere length or senescence between retinal and comparator endothelium, which would make peripheral non-perfusion a consequence of something other than endothelial replicative failure.

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"Nevertheless, the same mutations in TINF2 may be found in classical DKC patients presenting clinically without the distinct RS phenotype, hence, the genotype alone is not able to define RS"

The statement of the gap: identical genotype, different disease.

Do DC-cluster TIN2 variants shorten telomeres by failing to recruit telomerase, by causing a telomerase-independent replication defect, or by both?

OPEN QUESTION OPEN tin2_dc_mechanism_dispute

Attached to

pathophysiology#Impaired Shelterin-Mediated Telomere Maintenance mechanistic_hypotheses#tin2_telomerase_recruitment_defect mechanistic_hypotheses#tin2_telomere_replication_defect

Two well-executed studies reach different answers, and the disagreement is real rather than apparent. Human-cell work shows DC-cluster TIN2 mutants losing telomerase association while end protection is intact, which is a recruitment defect. Mouse knock-in work shows the same class of allele accelerating telomere shortening with telomerase RNA deleted entirely, which a recruitment defect cannot produce, together with ATR signalling and fragile telomeres. The most likely resolution is that both operate, in different compartments - recruitment failure in telomerase-positive stem cells, replication failure in telomerase-negative somatic tissue - which is what the mouse authors themselves propose. If that is right it has a consequence for this disease specifically: a replication defect in telomerase-negative tissue would predict damage in slowly renewing compartments such as retinal endothelium, which is exactly where this syndrome differs from classical marrow-limited disease. Nobody has tested that prediction.

Show evidence (1 reference)

PMID:24449270 SUPPORT Model Organism

"These data suggest that this TIN2-DC mutation could induce telomeric dysfunction phenotypes in telomerase-negative somatic cells and tissues that further exacerbate the telomere maintenance problems in telomerase-positive stem cell compartments."

The authors' own proposed reconciliation of the two mechanisms, and the source of the testable prediction about slowly renewing tissue.

Can any current model reproduce the retinal and CNS phenotypes that define Revesz syndrome?

HUMAN MODEL MISMATCH OPEN revesz_mouse_model_mismatch

Attached to

animal_models#Mouse pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy

The only in vivo model of a Revesz-window TINF2 allele is the TIN2(DC) knock-in mouse, and it models the wrong part of the disease. Its phenotype is mild pancytopenia appearing only in the second and third generations, because laboratory mice start with far longer telomeres than humans; first-generation heterozygotes are healthy and fertile. No ophthalmic or neuroimaging assessment is reported, so the model is silent rather than negative on the retinal and CNS branches. This is a HUMAN_MODEL_MISMATCH rather than a plain gap because a model does exist and is informative - it produced the telomerase-independent finding that the human system could not have - while being structurally unable to address the features that define the disease. Any model that could would need a short-telomere background, such as a late-generation telomerase-null mouse, or a human iPSC-derived retinal vascular system.

Show evidence (1 reference)

PMID:24449270 SUPPORT Model Organism

"Whereas homozygous TIN2(DC/DC) mice were not viable, first-generation TIN2(+/DC) mice were healthy and fertile."

The generational limitation that makes this model a poor match for an infantile human disease.

⚙

Pathophysiology

7

TINF2 Exon 6 Cluster Variant

A heterozygous germline TINF2 variant in a strikingly narrow window: every variant in genotyped Revesz patients has fallen in exon 6, between amino acids 280 and 289 of TIN2. The recurrent allele is c.845G>A, and the same residue - 282 - accounts for the majority of TINF2 dyskeratosis congenita variants generally. Frameshift alleles producing truncated TIN2 occur in the same window. That window is the "dyskeratosis congenita cluster" of TIN2, and its constancy is the single most distinctive genetic fact about this disease. It is also the fact that most undermines Revesz as a separate entity: the identical variants are found in patients with classical dyskeratosis congenita who never develop the retinopathy. The founding TINF2 paper makes the point in its own data, reporting R282H across three unrelated probands of whom only one had Revesz syndrome. Genotype therefore cannot define this disease, and no modifier that does has been identified.

TINF2 hgnc:11824

Genetic context TINF2 hgnc:11824 variant_origin: GERMLINE zygosity: HETEROZYGOUS

Heterozygous germline TINF2 variants confined to exon 6, amino acids 280-289; missense substitutions predominate, with frameshift alleles also reported. Almost always de novo. No functional_impact_category is recorded: the DC-cluster alleles are neither a clean loss of function nor a clean gain, and the two published mechanistic accounts of what they do to TIN2 disagree - see the mechanistic hypotheses below.

Downstream

Impaired Shelterin-Mediated Telomere Maintenance TIN2 is a structural hub of shelterin; a variant in its DC cluster impairs the complex's maintenance of telomere length. The step is direct, but which molecular activity is lost is disputed, so both hypothesis groups attach to the edge below it rather than here.

Show evidence (4 references)

PMID:33097095 SUPPORT Human Clinical

"All of these harbored a TINF2 mutation and the underlying alterations were restricted to exon six."

Establishes TINF2 exon 6 as the location of every variant found in genotyped Revesz patients.

PMID:33097095 SUPPORT Human Clinical

"Hence, all mutations were located between amino acid 280 and 289."

The nine-residue window that all reported Revesz alleles fall within.

PMID:18252230 SUPPORT Human Clinical

"We demonstrate that a fifth gene, TINF2, is mutated in classical DC and, for the first time, in Revesz syndrome."

The paper that first attached TINF2 to this disease, and in the same sentence to classical dyskeratosis congenita - the ambiguity the entity has carried ever since.

+ 1 more reference

Impaired Shelterin-Mediated Telomere Maintenance

Mechanism confidence: Provisional

Shelterin is the six-protein complex that coats the telomere and suppresses the DNA damage response there. TIN2 is its structural hub, binding TRF1 and TRF2 on the duplex telomeric DNA and TPP1 - and through TPP1, POT1 - on the single-stranded overhang. A DC-cluster variant leaves the complex assembled but impairs its regulation of telomere length. What exactly is impaired is genuinely disputed, and the two published accounts are set out as separate hypothesis groups rather than blended. One holds that DC-cluster TIN2 mutants lose the ability to recruit telomerase; the other, from a knock-in mouse, holds that they cause a telomerase-independent replication defect at the telomere. The experiments behind each are sound, they are not mutually exclusive, and no work has apportioned them.

DC-cluster TIN2 variants shorten telomeres by a telomerase-independent replication defect DC-cluster TIN2 variants shorten telomeres by impairing telomerase recruitment

TINF2 hgnc:11824

shelterin complex GO:0070187

telomere maintenance GO:0000723 ↓ DECREASED

telomeric region of the chromosome GO:0000781

Experimental models

Ectopic DC-cluster TIN2 missense expression in human cells CELL LINE Reproduces the molecular phenotype of a DC-cluster TIN2 allele - progressive telomere shortening - in human cells, and localises the defect to telomerase recruitment rather than to end protection.

Downstream

Extreme Telomere Shortening Under the recruitment model, the DC-cluster variant reduces TPP1-dependent delivery of telomerase to the telomere, so telomeres are not replenished and shorten with every division.

Extreme Telomere Shortening Under the replication model, the DC-cluster variant makes the telomere a fragile replication substrate, producing attrition that persists in the complete absence of telomerase.

Show evidence (2 references)

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

"It is caused by mutations in the TINF2 gene, which encodes a component of shelterin, a six-protein complex that coats the telomere and is essential for suppressing the DNA damage response at telomeres"

The expert panel's statement of the molecular role of the affected complex.

PMID:33097095 SUPPORT Human Clinical

"In RS, mutations in TINF2 at chromosome 14q11.2 result in dysfunctional TIN2 protein leading to impaired telomere protection by the shelterin complex"

The review's statement of this step as it applies specifically to Revesz syndrome.

Extreme Telomere Shortening

Telomeres far below the first age-adjusted percentile - shorter, as a group, than in any other genetic subtype of dyskeratosis congenita. In the assembled Revesz cohort every patient with a measurement had a very short result, and in a large TINF2 series the telomere lengths were the shortest of all dyskeratosis congenita subtypes while telomerase RNA levels were normal, which localises the defect to the telomere rather than to the enzyme. This is the quantitative link between the genotype and the severity, and the reason telomere length by flow-FISH is the functional screening test for the disease. Below some threshold, replication-limited tissues stop being replenished; which tissues fail first is what the branches below describe.

replicative senescence GO:0090399 ↑ INCREASED telomere maintenance via telomerase GO:0007004 ↓ DECREASED

Animal models

TIN2(DC) knock-in mouse (K280E equivalent) Mouse partially recapitulates Reproduces the central molecular consequence - progressive telomere attrition from a heterozygous DC-cluster TIN2 allele - and reproduces a mild haematopoietic phenotype downstream of it. It also produced the finding that the attrition is not solely telomerase-dependent, which the human system could not have shown.

Downstream

Hematopoietic Stem Cell Exhaustion The best-established branch, shared with all telomere biology disorders: the highest-turnover compartment fails first.

Retinal Peripheral Non-Perfusion and Exudative Vasculopathy The branch that defines this entity, and the one whose intermediates are unknown. No study has demonstrated the cellular step between short telomeres and a non-perfused peripheral retina.

Intracranial Calcification and Cerebrovascular Fragility The CNS branch, equally unresolved at the cellular level.

Pulmonary Involvement and Respiratory Failure The lung branch, shared with the telomere biology disorders generally, where alveolar epithelial replicative failure drives fibrosis. In this disease it matters mainly as a cause of death that transplantation does not remove.

Nail Dystrophy Revesz syndrome sits inside the dyskeratosis congenita spectrum, and the classic mucocutaneous triad is reached by the same route as in DC: replicative exhaustion of the high-turnover epithelia. Curated as three separate edges because the triad components are three distinct tissues.

Reticulated Skin Pigmentation The cutaneous component of the DC triad, in a continuously renewing epithelium.

Oral Leukoplakia The mucosal component of the DC triad.

Cerebellar Hypoplasia Shared with Hoyeraal-Hreidarsson syndrome, the other severe end of the telomere biology spectrum. Linked from the telomere node rather than from a tissue-exhaustion step because the cerebellum is not a high-turnover tissue and the route from telomere shortening to hypoplastic cerebellar development is not established.

Global Developmental Delay The functional counterpart of the structural brain findings. Mechanism unestablished, and the contribution of the intracranial calcification and haemorrhage curated elsewhere in this entry cannot be separated out.

Intrauterine Growth Restriction Prenatal growth failure, consistent with telomere reserve being exhausted before birth in the most severe variants. It is the earliest sign that this disease is not simply DC with an earlier onset.

Show evidence (3 references)

PMID:18669893 SUPPORT Human Clinical

"Telomere lengths in patients with TINF2 mutations were the shortest compared with other DC subtypes, but TERC levels were normal."

Places TINF2 patients at the extreme of telomere shortness among dyskeratosis congenita subtypes, with normal telomerase RNA - the observation that makes this a telomere defect rather than a telomerase-abundance defect.

PMID:33097095 SUPPORT Human Clinical

"Telomere analysis was available in seven patients. All presented with very short lengths"

The telomere-length finding in the Revesz cohort itself, in the seven patients who were measured.

PMID:39371255 SUPPORT Other

"Revesz and Hoyeraal-Hreidarsson syndrome are characterized by a severe disease course, very short telomeres (considerably below the 1% percentile), and a disease onset in the early childhood"

A recent review's statement of the telomere threshold that characterises the severe pediatric telomere biology disorders, Revesz among them.

Hematopoietic Stem Cell Exhaustion

Failure of the marrow's stem cell compartment to sustain haematopoiesis, producing progressive pancytopenia in the first years of life. This branch is shared in full with classical dyskeratosis congenita and with the other telomere biology disorders; what distinguishes Revesz syndrome is only how early it arrives. It is the usual cause of death and the target of the only potentially curative treatment.

Hematopoietic stem cell CL:0000037

bone marrow UBERON:0002371

Downstream

Bone Marrow Failure Exhaustion of the stem cell pool presents clinically as marrow failure.

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4-1.6)."

Establishes marrow failure as universal and infantile in this disease.

PMID:18669893 SUPPORT INDIRECT Human Clinical

"A total of 32 of 33 patients with DC with TINF2 mutations have severe disease, with most developing aplastic anaemia by the age of 10 years."

The severity and timing of marrow failure across TINF2 dyskeratosis congenita as a whole. INDIRECT because the cohort is TINF2 patients generally rather than Revesz patients; it shows the early-marrow-failure tendency is a property of the gene, not of the eponym.

Retinal Peripheral Non-Perfusion and Exudative Vasculopathy

Mechanism confidence: Hypothetical

The lesion that gives the syndrome its name: a bilateral peripheral retinal vasculopathy - avascular peripheral retina, telangiectasia, microaneurysms and fluorescein leakage - progressing to exudation, neovascularisation, vitreous haemorrhage and tractional retinal detachment. Angiographically it is indistinguishable from familial exudative vitreoretinopathy, Coats disease and cicatricial retinopathy of prematurity, and children with Revesz syndrome have been treated for all three before the systemic diagnosis was made. The cellular mechanism is not established. The plausible account is that the retinal microvascular endothelium, a slowly renewing compartment, reaches replicative failure at the extremely short telomeres these patients carry, so peripheral capillaries drop out and the resulting ischaemia drives the exudative and neovascular sequence. No study has demonstrated that step - there is no telomere measurement, senescence marker or endothelial study in Revesz retina - so the node is tagged HYPOTHETICAL and describes the observed vascular lesion rather than the inferred cell biology. A 2026 widefield angiography series changed how this node should be read. Peripheral non-perfusion was present in 100% of 44 eyes across 22 telomere biology disorder patients, most of whom were asymptomatic and none of whom would previously have been called Revesz syndrome. On that evidence the retinal branch is not a Revesz-specific limb of the pathograph at all; it is a universal telomere-disorder limb that becomes symptomatic earliest and most severely in these children.

Retinal microvascular endothelial cell CL:0002585

retina UBERON:0000966

Downstream

Bilateral Exudative Retinopathy Peripheral capillary dropout and leakage present clinically as exudative retinopathy.

Retinal Detachment Ischaemia drives neovascularisation, vitreous haemorrhage and fibrovascular traction, which detach the retina.

Glaucoma Secondary glaucoma, by the route the same ischaemia takes in other proliferative retinopathies: neovascularisation extends onto the iris and the drainage angle, obstructing aqueous outflow. Grouped under the vasculopathy node rather than treated as an independent ocular abnormality for that reason.

Show evidence (4 references)

PMID:42617951 SUPPORT Human Clinical

"For posterior segment findings, all eyes had some combination of peripheral non-perfusion (100%), microaneurysmal changes (63.6%), telangiectasias (54.5%), fluorescein leakage (54.5%), sclerotic vessels (40.1%), retinal hemorrhages (36.3%), exudates (27.3%), retinal neovascularization (13.6%),..."

The best-characterised description of the vascular lesion, quantified by widefield fluorescein angiography, and the source for the ordering from non-perfusion through leakage to neovascularisation and detachment.

PMID:42617951 SUPPORT Human Clinical

"Contrary to prior assumptions, the retinovascular abnormalities in patients with TBDs, including DC, were universal in our cohort."

The finding that makes this branch a telomere-disorder feature rather than a Revesz-specific one, and the basis for the nosological discussion below.

PMID:28095086 SUPPORT Human Clinical

"Revesz syndrome is a telomere disorder in the dyskeratosis congenita (DKC) spectrum characterized by exudative retinopathy, bone marrow failure, neuroradiographic abnormalities, and integumentary findings."

A retinal-specialist description of the entity, from the report of identical twins in whom the retinopathy was compared directly against the other paediatric retinal vasculopathies.

+ 1 more reference

Intracranial Calcification and Cerebrovascular Fragility

Mechanism confidence: Hypothetical

Progressive intracranial calcification, most often in the basal ganglia and thalami, together with cerebellar hypoplasia and white matter change, and in a minority intracranial haemorrhage. Calcification was present in 85% of the Revesz patients imaged and cerebellar hypoplasia in 76%. The mechanism is inferred rather than shown, and the inference is drawn from a neighbour disease. Cerebroretinal microangiopathy with calcifications and cysts - Coats plus, caused by CTC1 - produces an almost identical combination of exudative retinopathy and intracranial calcification through a small-vessel angiopathy, which is the main reason calcification here is read as a microvascular rather than a metabolic process. The haemorrhages reported in three Revesz children point the same way. Nothing in the Revesz literature demonstrates it: there is no neuropathology series and no vascular study, so this node is tagged HYPOTHETICAL and names the imaging finding rather than a cell mechanism. Cerebellar hypoplasia is grouped here for anatomical convenience but is probably not the same process. It is present from the earliest imaging rather than progressive, which makes it a developmental consequence of the telomere defect rather than an acquired vascular one.

brain UBERON:0000955

Downstream

Cerebral Calcification

Intracranial Hemorrhage Reported in three of the assembled patients and interpreted by the reviewing authors as possible cerebrovascular fragility. The intermediates are unknown and the number is small.

Seizures Attached here because intracranial calcification and haemorrhage are the structural lesions in this entry most likely to be epileptogenic. The attribution is inference rather than a reported mechanism, and the cerebellar and developmental abnormalities curated on the telomere node could contribute instead — no cited source separates them.

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13) were common features"

The frequencies of the two neuroimaging findings across the assembled cohort, with their denominators.

PMID:33097095 SUPPORT Human Clinical

"intracranial hemorrhage was detected in three patients during the course of the disease"

The haemorrhage observation that prompted the suggestion of cerebrovascular fragility. Three patients is the whole of it.

Pulmonary Involvement and Respiratory Failure

Mechanism confidence: Provisional

Lung disease as the third organ consequence of the telomere defect. Pulmonary fibrosis is a well-established feature of the telomere biology disorders as a class - GeneReviews names it among the risks of DC/TBD and recommends annual pulmonary function testing from around age eight - and its mechanism, replicative failure of the alveolar epithelial progenitor compartment, is the same one that empties the marrow. What is documented in Revesz syndrome specifically is narrower and more acute: refractory lung failure was a cause of death in some of the assembled patients, including after transplantation, and the index case died of aspiration pneumonia with refractory lung failure. No pulmonary function series, imaging series or histology exists for this disease, so the node is tagged PROVISIONAL and is careful not to assert established fibrosis in children who mostly die before eight. It is curated because it is a cause of death and because it is the branch that survives a successful transplant.

replicative senescence GO:0090399 ↑ INCREASED

lung UBERON:0002048

Downstream

Respiratory Failure

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"Patients died from BMF in most cases, but refractory lung failure was another cause of death in some cases."

The only disease-specific evidence for this branch, and the reason it is curated: lung failure killed some of these children.

PMID:20301779 SUPPORT INDIRECT Other

"People with DC/TBD are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome or acute myelogenous leukemia, solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis."

GeneReviews places pulmonary fibrosis among the established risks of the telomere biology disorders. INDIRECT because the statement is about DC/TBD as a class, not about Revesz syndrome, where fibrosis as such has not been documented.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

15

Blood 2

Bone Marrow Failure OBLIGATE Aplastic anemia HP:0001915

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4-1.6)."

Universality and timing of marrow failure across the assembled cohort.

Intracranial Hemorrhage OCCASIONAL HP:0002170

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"intracranial hemorrhage was detected in three patients during the course of the disease"

Three of eighteen, which places this in the OCCASIONAL band of 5-29%.

Eye 3

Bilateral Exudative Retinopathy OBLIGATE Exudative vitreoretinopathy HP:0030490

Course: PROGRESSIVE

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients."

The review's conclusion that retinopathy was present in all 18 assembled patients.

PMID:33097095 SUPPORT Human Clinical

"retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in three cases."

The visual outcome and the frequency of glaucoma as a complication.

Retinal Detachment HP:0000541

Show evidence (1 reference)

PMID:34189343 SUPPORT Human Clinical

"A 3-year-old Japanese girl with Revesz Syndrome had progressive vitreal hemorrhages and tractional retinal detachments in both eyes."

A documented case of bilateral tractional detachment in Revesz syndrome and its antecedent vitreous haemorrhage.

Glaucoma OCCASIONAL HP:0000501

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in three cases."

Three of eighteen, which places this in the OCCASIONAL band of 5-29%, reported alongside the visual outcome it follows from.

Head and Neck 1

Oral Leukoplakia FREQUENT HP:0002745

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings, and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n = 13/15) of patients with information, respectively."

The 43% figure for oral leukoplakia, the first of the three percentages. FREQUENT is the band containing 43%.

Integument 2

Nail Dystrophy VERY_FREQUENT HP:0008404

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings, and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n = 13/15) of patients with information, respectively."

The 87% figure for nail dystrophy, the third of the three percentages in the sentence. VERY_FREQUENT is the band containing 87%.

Reticulated Skin Pigmentation FREQUENT HP:0007427

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings, and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n = 13/15) of patients with information, respectively."

The 55% figure for hyperpigmented skin findings, the second of the three percentages. FREQUENT is the band containing 55%.

Musculoskeletal 1

Cerebral Calcification VERY_FREQUENT HP:0002514

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13) were common features"

The 85% figure, with its denominator of 13 patients who had the relevant information. VERY_FREQUENT is the FrequencyEnum band containing 85%.

Nervous System 3

Cerebellar Hypoplasia FREQUENT HP:0001321

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13) were common features"

The 76% figure with its denominator. FREQUENT is the FrequencyEnum band containing 76%.

Global Developmental Delay FREQUENT HP:0001263

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"this was present in 71% of patients (n = 12/17), frequently emerging during infancy."

The 71% figure and its denominator. FREQUENT is the FrequencyEnum band containing 71%.

Seizures OCCASIONAL HP:0001250

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"The incidence of seizures was low and was present in an estimated 20% of patients."

The 20% estimate, which sits in the OCCASIONAL band of 5-29%.

Respiratory 1

Respiratory Failure HP:0002878

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"Patients died from BMF in most cases, but refractory lung failure was another cause of death in some cases."

Records refractory lung failure as a cause of death in this cohort, without a denominator.

Cellular 1

Very Short Telomeres Short telomere length HP:0031413

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"Telomere analysis was available in seven patients. All presented with very short lengths"

The telomere result in every Revesz patient in whom it was measured, and the denominator that measurement rests on.

Growth 1

Intrauterine Growth Restriction Intrauterine growth retardation HP:0001511

Show evidence (1 reference)

PMID:39371255 SUPPORT Other

"Revesz syndrome typically features bilateral exudative retinopathy, intracranial calcification, cerebellar hypoplasia thereby causing ataxia, (intrauterine) growth restriction, general developmental delay, and fine hairs."

A recent review's feature list for the syndrome, which includes intrauterine growth restriction among the typical findings.

🧬

Genetic Associations

1

TINF2 (TINF2 encodes TIN2, the structural hub of the shelterin complex. Its link to this disease was established in the same 2008 paper that first connected shelterin to human disease at all, which reported TINF2 variants in classical dyskeratosis congenita probands and, for the first time, in a patient with Revesz syndrome. Every genotyped Revesz patient published since 2010 has carried a TINF2 variant in exon 6. The gene-disease relationship is not in doubt: ClinGen's Interstitial Lung Disease Gene Curation Expert Panel rates TINF2 Definitive, having reached the maximum genetic evidence score. What is in doubt is the disease boundary. That same curation applied the ClinGen Lumping and Splitting Working Group criteria and lumped Revesz syndrome with autosomal dominant dyskeratosis congenita 3, Hoyeraal-Hreidarsson syndrome and pulmonary fibrosis into one entity, TINF2-related short telomere syndrome, finding no difference in molecular mechanism or inheritance between them. The clinical genetics supports that reading rather than contradicting it. The recurrent R282H allele appears across probands with classical dyskeratosis congenita, with Revesz syndrome and with overlapping presentations, and the Karremann review states plainly that genotype alone cannot define Revesz syndrome. No modifier locus, second hit or environmental factor explaining who develops the retinal and CNS phenotype has been identified.)

Gene: TINF2 hgnc:11824 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (5 references)

PMID:18252230 SUPPORT Human Clinical

"We demonstrate that a fifth gene, TINF2, is mutated in classical DC and, for the first time, in Revesz syndrome."

The founding gene-disease claim for this entity.

PMID:18252230 SUPPORT Human Clinical

"TINF2 R282H in three additional unrelated DC probands, including one with Revesz syndrome"

The same allele in three unrelated probands of whom only one had Revesz syndrome - the original demonstration, in the founding paper's own data, that the genotype does not determine the phenotype.

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

The expert-panel classification row. Note the curated disease term is autosomal dominant dyskeratosis congenita 3, not Revesz syndrome - there is no Revesz-specific ClinGen curation, because the panel folded Revesz into this one.

+ 2 more references

🗃️

External Assertions

1

ClinGen TINF2 gene-disease validity assertion and lumping decision

ClinGen gene disease validity CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z

Recorded because it is two assertions in one, and the second is about this entry's right to exist. The ClinGen Interstitial Lung Disease Gene Curation Expert Panel rates TINF2 Definitive for the disease it curates, approved November 2024 under SOP11. In reaching that classification it applied the ClinGen Lumping and Splitting Working Group criteria and merged four separately named conditions - autosomal dominant dyskeratosis congenita 3, Revesz syndrome, Hoyeraal-Hreidarsson syndrome and pulmonary fibrosis - into a single entity, TINF2-related short telomere syndrome, on the ground that no difference in molecular mechanism or inheritance pattern separates them. dismech does not currently curate that lumped entity, and MONDO, OMIM and Orphanet all still carry Revesz syndrome as a distinct concept. This entry therefore curates the MONDO term as it exists while recording, prominently, that a criteria-based expert decision has already merged it away.

Show evidence (3 references)

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

"Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism or inheritance pattern between these conditions suggesting that these may constitute a disease spectrum associated with variants in TINF2 ."

The reasoning behind the lumping decision, and the strongest single argument against treating Revesz syndrome as a separate disease.

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

"have been lumped into one disease entity– TINF2 -related short telomere syndrome."

The decision itself, naming the entity Revesz syndrome was merged into.

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z SUPPORT Other

"Two forms of DC/TBD with more severe manifestations have been identified, Hoyeraal Hreidarsson syndrome, and Revesz syndrome, which were previously thought to be distinct disorders, but are now recognized to be part of the phenotypic spectrum of DC"

The panel's summary of the current nosological position: distinct disorder previously, severity band on dyskeratosis congenita now.

💊

Medical Actions

4

Allogeneic Hematopoietic Stem Cell Transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

The only potentially curative treatment for the marrow failure, and the only intervention that has demonstrably changed survival in this disease. Eight of the eighteen assembled children were transplanted and four were alive at last follow-up, a median of 22 months afterwards. Conditioning matters more here than in most transplant indications. Alkylators and radiation damage the same DNA-repair-limited tissues the disease already compromises, so reduced-intensity, radiation-sparing regimens are used; the children in this series who received fludarabine, cyclophosphamide and anti-thymocyte globulin tolerated transplant without severe early toxicity. Transplantation corrects the haematopoietic branch of the pathograph and nothing else: the retinal, pulmonary and CNS branches continue, and refractory lung failure remains a cause of death after transplant.

Mechanism Target:

Hematopoietic Stem Cell Exhaustion — Replaces the exhausted stem cell compartment with donor cells whose telomeres are of normal length. It does not correct the germline defect in any other tissue.

Show evidence (3 references)

PMID:33097095 SUPPORT Human Clinical

"Stem cell transplantation (SCT) was performed in eight children, and after a median of 22 months from SCT four of these patients were alive at the last follow up visit."

The whole of the transplant outcome data in this disease: eight patients, four alive at a median of under two years.

PMID:33097095 SUPPORT INDIRECT Human Clinical

"Patients died from BMF in most cases, but refractory lung failure was another cause of death in some cases."

The limit of what transplantation achieves. INDIRECT because the sentence describes causes of death across the whole cohort rather than a transplant outcome specifically; it is quoted to show the non-haematopoietic branches persist.

PMID:20301779 SUPPORT INDIRECT Other

"Hematopoietic cell transplantation (HCT) is the only curative treatment for BMF and leukemia, but long-term outcome has historically been poor due to treatment toxicity"

The GeneReviews management statement for this disease class, which is both the justification for transplanting these children and the reason conditioning is chosen the way it is. INDIRECT because the chapter addresses DC/TBD as a whole.

Retinal Laser Photocoagulation

Action: laser photocoagulation Ontology label: Laser Photocoagulation NCIT:C217424

Platform: Device

Ablation of the non-perfused peripheral retina to remove the ischaemic drive to neovascularisation. It is the primary ophthalmic treatment proposed in the only systematic series of telomere-disorder retinopathy, with anti-VEGF reserved for angiographically active eyes. The evidence is a case series with a proposed staging system, not a trial, and in the assembled Revesz cohort retinopathy still led to severe visual loss in most children despite treatment. What laser can plausibly do is preserve some vision if applied before the exudative and tractional stages, which is the argument for angiographic screening rather than for treating established disease.

Mechanism Target:

Retinal Peripheral Non-Perfusion and Exudative Vasculopathy — Ablates the ischaemic peripheral retina, interrupting the ischaemia-to-neovascularisation step. It does not address the telomere defect that produced the non-perfusion.

Show evidence (2 references)

PMID:42617951 SUPPORT Human Clinical

"We propose a staging system and discuss management strategies, including laser photocoagulation as the primary treatment, with adjunctive anti-VEGF agents for vascularly active eyes and vitreoretinal surgery for vitreous hemorrhage and retinal detachment."

The management proposal from the largest angiographic series, including the place of laser relative to anti-VEGF and surgery.

PMID:33097095 NO_EVIDENCE Human Clinical

"retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in three cases."

The visual outcome despite treatment across the assembled cohort. NO_EVIDENCE because the sentence reports an outcome in a mixed, uncontrolled group rather than an assessment of whether treatment helped; it neither supports nor refutes laser efficacy, and is quoted so the treatment is not read as effective on this evidence.

Pars Plana Vitrectomy

Action: vitrectomy Ontology label: Vitrectomy NCIT:C50837

Platform: Surgery

Vitreoretinal surgery for the end-stage ocular complications - vitreous haemorrhage and tractional retinal detachment. Anatomical reattachment with some visual improvement has been achieved in individual Revesz patients, in one report after repeated surgery on the worse eye, so surgery is worth offering rather than withholding on grounds of prognosis. The evidence is single case reports.

Mechanism Target:

Retinal Detachment — Relieves vitreoretinal traction and clears haemorrhage so the retina can reattach. Purely anatomical; the underlying vasculopathy is untouched.

Show evidence (1 reference)

PMID:34189343 SUPPORT Human Clinical

"A retinal attachment with vision improvement was achieved by a single surgery for the right eye and after repeated surgeries for the left eye."

The surgical outcome in the one Revesz patient reported in detail, including that the left eye needed repeated surgery.

Multisystem Surveillance and Supportive Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Platform: Other

Because transplantation corrects only the haematopoietic branch, surveillance of the other branches continues afterwards: ophthalmic review, pulmonary assessment, and the hepatic and malignancy surveillance that applies across telomere biology disorders. There is no Revesz-specific surveillance protocol; the telomere biology disorder guidance applies, which for marrow means annual blood counts with bone marrow examination and for the lung means annual pulmonary function testing once the child can perform it. GeneReviews also lists things to avoid, and two of them matter directly in a disease where eight of eighteen published patients were transplanted: non-leukodepleted and non-irradiated blood products, and blood donation by family members while transplantation is under consideration, since a related donor who is an unrecognised carrier is a real risk when the variant is dominant. The androgen plus granulocyte colony-stimulating factor combination is also to be avoided because of splenic rupture. That is a distinct claim from androgen efficacy, which this entry does not curate.

Mechanism Target:

Extreme Telomere Shortening — Detects the consequences of the shared upstream defect in each affected organ; it does not modify it.

Show evidence (4 references)

PMID:39371255 SUPPORT Other

"Revesz syndrome typically features bilateral exudative retinopathy, intracranial calcification, cerebellar hypoplasia thereby causing ataxia, (intrauterine) growth restriction, general developmental delay, and fine hairs."

The multisystem feature list that determines which specialties surveillance has to cover.

PMID:20301779 SUPPORT INDIRECT Other

"For BMF: complete blood count (CBC) annually if normal and more often if abnormal; annual bone marrow aspirate and biopsy."

The haematological surveillance schedule GeneReviews specifies for this disease class. INDIRECT because it is written for DC/TBD generally; in a disease where marrow failure arrives at a median of eighteen months, annual counts are a floor rather than a schedule.

PMID:20301779 SUPPORT INDIRECT Other

"For pulmonary fibrosis: annual pulmonary function tests starting either at diagnosis or when the individual can perform the test (often age ~8 years); bubble echocardiogram to look for pulmonary arteriovenous malformations if suspected based on clinical symptoms."

The pulmonary surveillance recommendation, and worth reading against this disease's median survival of 6.5 years: most of these children never reach the age at which the recommended test becomes performable.

+ 1 more reference

🔬

Diagnosis

3

Telomere Length Measurement by Flow-FISH

Age-adjusted lymphocyte telomere length below the first percentile is the functional screening test for a telomere biology disorder and is the single most discriminating investigation in a child with unexplained exudative retinopathy and cytopenias. Revesz patients sit far below that threshold - shorter, as a group, than any other dyskeratosis congenita subtype.

Show evidence (3 references)

PMID:39371255 SUPPORT Other

"Revesz and Hoyeraal-Hreidarsson syndrome are characterized by a severe disease course, very short telomeres (considerably below the 1% percentile), and a disease onset in the early childhood"

The telomere-length threshold that identifies the severe pediatric telomere biology disorders.

PMID:18669893 SUPPORT Human Clinical

"Telomere lengths in patients with TINF2 mutations were the shortest compared with other DC subtypes, but TERC levels were normal."

Why the test is particularly discriminating for TINF2 disease specifically.

PMID:20301779 SUPPORT INDIRECT Other

"A majority of individuals with DC/TBD have abnormally short telomeres for their age, as determined by multicolor flow cytometry fluorescence in situ hybridization (flow-FISH) on lymphocyte subsets."

The GeneReviews statement of the primary diagnostic test for this disease class, naming the assay and the tissue. INDIRECT because the chapter covers DC/TBD as a whole; there is no Revesz-specific GeneReviews chapter, which is itself consistent with this entry's argument that Revesz is not separable from TINF2 dyskeratosis congenita.

Widefield Fluorescein Angiography of the Retina

Widefield fluorescein angiography demonstrates the peripheral non-perfusion, telangiectasia and leakage that define the retinal lesion, and does so before the child is symptomatic. The 2026 series that established this found 18 of 22 patients asymptomatic at the time their retinal abnormality was detected on screening, which changes the test from a confirmatory one into a surveillance one for anybody with a telomere biology disorder.

Show evidence (2 references)

PMID:42617951 SUPPORT Human Clinical

"A total of 44 eyes from 22 patients were included (59.1% males)."

The size of the imaging series behind this recommendation. Small, and the only one of its kind.

PMID:42617951 SUPPORT Human Clinical

"Contrary to prior assumptions, the retinovascular abnormalities in patients with TBDs, including DC, were universal in our cohort."

The finding that makes angiographic screening worthwhile across telomere biology disorders rather than only in children already diagnosed with Revesz syndrome.

TINF2 Sequencing

Sequencing TINF2, or a telomere biology disorder panel, confirms the molecular diagnosis. In this disease the yield is concentrated: every reported variant lies in exon 6. A positive result establishes a telomere biology disorder but does not by itself establish Revesz syndrome, because the same alleles occur in patients without the retinal and CNS phenotype. The diagnosis remains clinical.

Show evidence (3 references)

PMID:33097095 SUPPORT Human Clinical

"All of these harbored a TINF2 mutation and the underlying alterations were restricted to exon six."

The concentration of variants in a single exon, which is what makes targeted sequencing high-yield here.

PMID:33097095 SUPPORT Human Clinical

"Nevertheless, the same mutations in TINF2 may be found in classical DKC patients presenting clinically without the distinct RS phenotype, hence, the genotype alone is not able to define RS"

Why a positive TINF2 result is not a diagnosis of this particular entity.

PMID:20301779 SUPPORT INDIRECT Other

"Pathogenic variants in one of these 16 genes have been identified in approximately 80% of individuals who meet clinical diagnostic criteria for DC/TBD."

The diagnostic yield of sequencing across the disease class, and the reason a negative panel does not exclude a telomere biology disorder. INDIRECT because the 80% figure is for DC/TBD generally; in genotyped Revesz patients the yield has been complete, but on twelve patients that is not a comparable statistic.

📈

Progression

3

Retinopathy onset

Age: 6 to 18 months

Retinopathy is typically the first manifestation, preceding marrow failure by months. That ordering matters clinically: several children were first diagnosed with retinopathy of prematurity, Coats disease or familial exudative vitreoretinopathy and only later recognised as having a telomere biology disorder.

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years; 95% CI 0.7-1.5)."

The reported timing of retinopathy onset across the assembled cohort.

Bone marrow failure

Age: birth to 6 years, median 1.5 years

Marrow failure follows the retinopathy and is the usual cause of death.

Show evidence (1 reference)

PMID:33097095 SUPPORT Human Clinical

"All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4-1.6)."

The reported timing and universality of marrow failure.

Death in childhood

Age: median 6.5 years, none beyond 12 years

Survival is the sharpest quantitative difference between this entity and classical dyskeratosis congenita, where survival into adulthood is ordinary. Whether that difference justifies a separate disease label or simply marks the severe tail of one disease is the nosological question this entry does not settle.

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"The Kaplan-Meier estimate of survival was dismal (median survival 6.5 years; 95% CI 3.6-9.4), and none of the patients survived beyond the age of 12 years."

The survival analysis across all 18 assembled cases.

PMID:33097095 SUPPORT Human Clinical

"Patients died from BMF in most cases, but refractory lung failure was another cause of death in some cases."

The reported causes of death, including the pulmonary complication that is the shared telomere-disorder endpoint.

📊

Prevalence

1

Worldwide, published cases

Cases In Literature Ultra Rare

No prevalence or incidence estimate exists. The largest analysis assembled 18 children from the entire English-language literature up to 2020, which is the whole denominator the disease has. ULTRA_RARE is the qualitative band; no numeric prevalence_class tier is recorded because no numeric estimate exists to place in one.

Show evidence (2 references)

PMID:33097095 SUPPORT Human Clinical

"The literature review included 18 children."

The size of the only assembled cohort, and therefore of the entire clinical evidence base for this disease.

PMID:33097095 SUPPORT Human Clinical

"Revesz syndrome is an extremely rare disorder, and to date, patients have only been published anecdotally."

The review's own characterisation of the evidence base as anecdotal, which is why no rate is recorded.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Revesz Syndrome:

Hoyeraal-Hreidarsson Syndrome

Overlapping Features The other severe infantile variant of dyskeratosis congenita, and the closest relative. Shares cerebellar hypoplasia, intrauterine growth restriction and early marrow failure with Revesz syndrome, and was lumped with it into the same TINF2 entity by ClinGen. Distinguished clinically by microcephaly, progressive immunodeficiency and more severe cognitive impairment, and by the absence of the exudative retinopathy - although proliferative retinopathy has been reported in Hoyeraal-Hreidarsson too, which weakens that boundary as well.

Distinguishing Features

Microcephaly and progressive immunodeficiency, which are not features of Revesz syndrome.
Not confined to TINF2 - Hoyeraal-Hreidarsson syndrome also arises from RTEL1, TERT, ACD, PARN and DKC1 variants.

Show evidence (1 reference)

PMID:39371255 SUPPORT Other

"Hoyeraal-Hreidarsson syndrome, on the other hand, shares some signs of Revesz syndrome such as cerebellar hypoplasia and intrauterine growth restriction, but can also present with progressive immunodeficiency, microcephaly, and moderate to severe mental retardation."

The overlap and the distinguishing features, stated side by side by a recent review.

Coats Plus Syndrome

Overlapping Features Cerebroretinal microangiopathy with calcifications and cysts, caused by biallelic CTC1 variants. It reproduces the Revesz combination of bilateral exudative retinopathy and intracranial calcification through a different telomere-maintenance gene, and the two were described in the literature as having key similarities before either gene was known. It is the most instructive differential in this file, because it shows the Revesz phenotype is reachable from a different lesion in the same pathway - which argues that the retinal and CNS branches are a property of severe telomere dysfunction rather than of TINF2. dismech does not yet curate Coats plus; the two entities should be decided together.

Distinguishing Features

Autosomal recessive CTC1 variants rather than dominant TINF2, and intracranial cysts and leukodystrophy in addition to calcification.
Telomere length is not necessarily reduced, which limits the value of telomere-length screening in distinguishing it.
Bone marrow failure, when it occurs, is later - adolescence or early adulthood rather than infancy - and gastrointestinal bleeding is prominent.

Show evidence (1 reference)

PMID:39371255 SUPPORT Other

"Early severe pediatric forms of TBDs with often characteristic underlying genetic variants are the Revesz syndrome, the Hoyeraal-Hreidarsson syndrome, and the Coats plus syndrome"

Groups the three severe paediatric telomere biology disorders together, which is the differential set a clinician faces.

Retinopathy of Prematurity

Overlapping Features Included because it is the misdiagnosis that has actually happened. Revesz syndrome presents with bilateral peripheral retinal non-perfusion in an infant, frequently one born preterm or small for gestational age, which is precisely the setting in which retinopathy of prematurity is expected. At least one child was treated with bilateral laser for presumed retinopathy of prematurity before the systemic diagnosis emerged, and others were managed as Coats disease or familial exudative vitreoretinopathy.

Distinguishing Features

Cytopenias, growth restriction and nail or skin change accompanying the retinopathy, none of which belong to retinopathy of prematurity.
Progression or new exudative change after the window in which retinopathy of prematurity would be expected to stabilise.

Show evidence (1 reference)

PMID:35724369 SUPPORT Human Clinical

"We report the case of a 2-year-old male child, initially treated with bilateral laser photocoagulation for retinopathy of prematurity. He developed exudative changes in the right eye, presumed to be Coats disease."

A documented case in which Revesz syndrome was treated first as retinopathy of prematurity and then as Coats disease before the diagnosis was made.

🔬

Clinical Trials

2

NCT01659606 PHASE_II ACTIVE_NOT_RECRUITING

Radiation- and alkylator-free haematopoietic cell transplantation for marrow failure due to dyskeratosis congenita and telomere disease. The ClinicalTrials.gov record lists Revesz syndrome among its conditions alongside dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome and aplastic anaemia. Its premise is exactly the conditioning problem this disease poses: DNA-damaging conditioning agents worsen the lung, liver and cancer risk that short telomeres already create.

Show evidence (1 reference)

clinicaltrials:NCT01659606 SUPPORT Human Clinical

"Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA damaging agents in patients with DC, and still have a successful BMT."

The trial's stated hypothesis, which is the rationale behind the reduced-intensity conditioning already used in the Revesz patients who were transplanted.

NCT06817590 PHASE_I RECRUITING

Oral nucleoside therapy in telomere biology disorders. The ClinicalTrials.gov record lists Revesz syndrome among its conditions. This is the only trial of a systemic, mechanism-directed treatment for which patients with this disease are eligible; it is phase I, and no efficacy claim should be read into its existence.

Show evidence (1 reference)

clinicaltrials:NCT06817590 SUPPORT Human Clinical

"The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders."

The trial's stated objective and enrolled population, which is the class this disease belongs to. Quoted to establish eligibility, not to make any claim about the intervention - it is a phase I safety study.

🧫

Experimental Models

1

Ectopic DC-cluster TIN2 missense expression in human cells CELL_LINE

Human cells expressing TIN2 carrying dyskeratosis congenita cluster missense mutations. The system reproduces accelerated telomere shortening and was used to establish what the mutants can and cannot do: they lose telomerase association while leaving total telomerase activity, TIN2 localisation and telomere end protection intact.

Organism

human NCBITaxon:9606

Publication

PMID:21536674

Pathograph links

Impaired Shelterin-Mediated Telomere Maintenance recapitulates fidelity: moderate Reproduces the molecular phenotype of a DC-cluster TIN2 allele - progressive telomere shortening - in human cells, and localises the defect to telomerase recruitment rather than to end protection.

Limitations: Ectopic overexpression on a wild-type background, not the heterozygous endogenous state of a patient; transformed cell lines rather than the stem cell compartments that fail in the disease; and a molecular readout with no tissue phenotype. It also cannot address the telomerase-independent component that the mouse work later identified, because the system retains endogenous telomerase throughout.

Readouts

Telomere length in cells expressing DC-mutant TIN2

Direction: DECREASED

Interpretation: Accelerated telomere shortening, reproducing the patient phenotype in a controlled human cell system.

Show evidence (1 reference)

PMID:21536674 SUPPORT In Vitro

"ectopic expression of TIN2 with DC missense mutations in human cells led to accelerated telomere shortening, similar to the telomere phenotypes found in DC patients"

The telomere-length readout and the authors' own comparison of it to the patient phenotype.

Total cellular telomerase activity and telomere end protection status

Direction: UNCHANGED

Interpretation: A negative result that carries the argument: the shortening is not explained by less telomerase or by loss of end protection, which is what narrows the defect to recruitment.

Show evidence (1 reference)

PMID:21536674 SUPPORT In Vitro

"However, this telomere shortening was not accompanied by changes in total telomerase activity, localization of TIN2, or telomere end protection status."

The three measurements that were unchanged, and the reason the conclusion is specific.

🐁

Animal Models

1

TIN2(DC) knock-in mouse (K280E equivalent)

A gene-targeted mouse carrying the murine equivalent of TIN2 K280E, a dyskeratosis congenita cluster allele that falls inside the same 280-289 window as every reported Revesz variant. Homozygotes are inviable; heterozygotes are healthy in the first generation and develop mild pancytopenia and reduced fecundity only in the second and third, as bone marrow telomeres shorten across generations. It is the only in vivo model of a Revesz-window TINF2 allele. It is emphatically not a model of Revesz syndrome.

Species

Mouse

Genotype

Tinf2 knock-in, equivalent of human TIN2 K280E dyskeratosis congenita allele, heterozygous

Genes

TINF2 hgnc:11824

Publication

PMID:24449270

Pathograph links

Extreme Telomere Shortening partially recapitulates fidelity: low Reproduces the central molecular consequence - progressive telomere attrition from a heterozygous DC-cluster TIN2 allele - and reproduces a mild haematopoietic phenotype downstream of it. It also produced the finding that the attrition is not solely telomerase-dependent, which the human system could not have shown.

Limitations: Laboratory mice begin with telomeres several times longer than human telomeres, so a single generation cannot reach a pathogenic length; the phenotype only appears after successive intercrosses, which is a breeding artefact with no human counterpart. The haematopoietic phenotype is mild pancytopenia in adult mice rather than the fatal infantile marrow failure of this disease. Neither the retinal nor the cerebral branch of the human pathograph was assessed - the paper reports no ophthalmic or neuroimaging examination - so this model says nothing about the two features that define Revesz syndrome, and its silence on them is untested rather than negative.

Readouts

Bone marrow telomere length across successive generations

Direction: DECREASED

Interpretation: The core readout: telomeres in the haematopoietic compartment shorten progressively over generations in heterozygotes, the murine counterpart of the very short telomeres measured in patients.

Show evidence (1 reference)

PMID:24449270 SUPPORT Model Organism

"Bone marrow telomeres of TIN2(+/DC) mice shortened over the generations, and immortalized TIN2(+/DC) mouse embryonic fibroblasts (MEFs) showed telomere shortening with proliferation."

The telomere measurement in marrow and in fibroblasts that grounds this readout.

Peripheral blood counts in second- and third-generation heterozygotes

Direction: DECREASED

Interpretation: The haematopoietic consequence, and the point at which the model's severity diverges sharply from the human disease: mild pancytopenia in later generations of adult mice versus universal marrow failure by age six in children.

Show evidence (1 reference)

PMID:24449270 SUPPORT Model Organism

"In the second and third generations, the TIN2(+/DC) mice developed mild pancytopenia, consistent with hematopoietic dysfunction in DC, as well as diminished fecundity."

The blood-count phenotype, and the generation at which it appears.

Show evidence (2 references)

PMID:24449270 SUPPORT Model Organism

"we generated mice with the equivalent of the TIN2 K280E DC allele (TIN2(DC)) by gene targeting"

Establishes the allele modelled, which lies inside the same exon-6 window as every reported Revesz variant.

PMID:24449270 SUPPORT Model Organism

"Whereas homozygous TIN2(DC/DC) mice were not viable, first-generation TIN2(+/DC) mice were healthy and fertile."

The generational limitation that governs how this model must be interpreted: a first-generation heterozygote is normal.

{ }

Source YAML

click to show

name: Revesz Syndrome
creation_date: "2026-08-31T18:00:00Z"
category: Mendelian
disease_term:
  preferred_term: Revesz syndrome
  term:
    id: MONDO:0009990
    label: Revesz syndrome
synonyms:
- DKCA5
- dyskeratosis congenita, autosomal dominant 5
- dyskeratosis congenita with bilateral exudative retinopathy
- retinopathy-anemia-central nervous system anomalies syndrome
- exudative retinopathy with bone marrow failure
- Revesz-Debuse syndrome
- TINF2-associated Revesz syndrome
description: >-
  The severe infantile end of the telomere biology disorder spectrum: bilateral exudative
  retinopathy and bone marrow failure, both beginning in the first two years of life, with
  intracranial calcification, cerebellar hypoplasia, growth restriction and a median survival
  of six and a half years. It is caused by heterozygous TINF2 variants in a nine-residue
  window of exon 6, almost always de novo. Fewer than twenty patients have ever been
  described with enough clinical detail to analyse.

  **This entry curates a diagnostic label that two authorities are actively trying to
  retire, and that is the most important thing in it.** In November 2024 ClinGen's
  Interstitial Lung Disease Gene Curation Expert Panel applied the Lumping and Splitting
  Working Group criteria to TINF2 and lumped Revesz syndrome (OMIM 268130) together with
  autosomal dominant dyskeratosis congenita 3, Hoyeraal-Hreidarsson syndrome and pulmonary
  fibrosis into a single entity, TINF2-related short telomere syndrome, on the ground that
  no difference in molecular mechanism or inheritance pattern separates them. In August 2026
  a 22-patient widefield fluorescein angiography study found retinovascular abnormality in
  every eye of every telomere biology disorder patient examined - 81.8% of them asymptomatic -
  and proposed replacing the eponym with Short Telomere Associated Retinopathy. If the
  defining feature is universal in the parent disease once you look for it properly, Revesz
  syndrome names a point on a severity continuum rather than a separate disease.

  Three things nevertheless make this worth a file of its own rather than a line on
  Dyskeratosis Congenita. The mechanism is not where the two differ - upstream, Revesz is
  TINF2 dyskeratosis congenita and nothing else - but the *tissues that fail* are. The
  dismech Dyskeratosis Congenita pathograph runs telomere attrition to senescence to stem
  cell exhaustion to marrow, lung and liver, and has no retinal and no CNS limb at all; those
  limbs are what this file adds. Second, that entry's has_subtypes list is keyed by gene, and
  Revesz is not a gene: the same TINF2 alleles produce classical dyskeratosis congenita in
  other patients, which the Karremann review states outright. Third, a Subtype record in this
  schema carries a name, a term, genes and inheritance - it cannot carry pathophysiology,
  progression, treatments or models - so recording Revesz as a subtype would bind the MONDO
  term and discard the mechanism.

  What is *not* claimed here: that Revesz is genetically or mechanistically separable from
  TINF2 dyskeratosis congenita. It is not, and the entry says so repeatedly. The open
  question - why the retina and the cerebral microvasculature fail catastrophically in these
  children and not in other carriers of the same variant - is curated as a knowledge gap
  rather than papered over.

parents:
- Dyskeratosis Congenita
- Telomere Biology Disorder
- Inherited Bone Marrow Failure Syndrome

classifications:
  iuis_category:
    classification_value: bone marrow failure
    notes: >-
      IUIS 2022 phenotypic classification of inborn errors of immunity (Tangye et
      al., PMID:35748970), Table 9 "Bone marrow failure", the DKCA5 row of the
      dyskeratosis congenita block. The table gives that row as "DKCA5 TINF2 AD
      268130". It names no eponym, so the identification runs through the OMIM
      number: 268130 is Revesz syndrome, and this entry carries both "DKCA5" and
      "dyskeratosis congenita, autosomal dominant 5" in its synonym list for exactly
      that reason. The row is therefore this disease under its OMIM-keyed label, not
      a separate entity. Two things this assignment does not claim. It does not
      claim IUIS treats Revesz as distinct from dyskeratosis congenita, since the
      row sits inside the DC block and shares its category cell; the parent entry
      Dyskeratosis Congenita carries the same value against the block as a whole.
      And it does not resolve the lumping question described in this entry's
      description, where ClinGen would fold Revesz into TINF2-related short telomere
      syndrome; IUIS 2022 predates that call and lists the OMIM row as it stood.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "DKCA4 RTEL1 AD 616373 DKCA5 TINF2 AD 268130 DKCA6 ACD AD 616553"
      explanation: >-
        The DKCA5 row of the Table 9 dyskeratosis congenita block, giving TINF2,
        autosomal dominant inheritance and OMIM 268130, the phenotype number for
        Revesz syndrome. Quoted together with the adjacent DKCA4 and DKCA6 rows
        because the DKCA5 row alone is four tokens and falls below the minimum
        snippet length; only the middle triple bears on this claim. Graded OTHER
        because the cited source is an expert-committee nosology, not a primary
        study.

prevalence:
- population: Worldwide, published cases
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    No prevalence or incidence estimate exists. The largest analysis assembled 18 children
    from the entire English-language literature up to 2020, which is the whole denominator
    the disease has. ULTRA_RARE is the qualitative band; no numeric prevalence_class tier is
    recorded because no numeric estimate exists to place in one.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The literature review included 18 children.
    explanation: >-
      The size of the only assembled cohort, and therefore of the entire clinical evidence
      base for this disease.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Revesz syndrome is an extremely rare disorder, and to date, patients have only been
      published anecdotally.
    explanation: >-
      The review's own characterisation of the evidence base as anecdotal, which is why no
      rate is recorded.

progression:
- phase: Retinopathy onset
  age_range: 6 to 18 months
  notes: >-
    Retinopathy is typically the first manifestation, preceding marrow failure by months.
    That ordering matters clinically: several children were first diagnosed with retinopathy
    of prematurity, Coats disease or familial exudative vitreoretinopathy and only later
    recognised as having a telomere biology disorder.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years;
      95% CI 0.7-1.5).
    explanation: >-
      The reported timing of retinopathy onset across the assembled cohort.

- phase: Bone marrow failure
  age_range: birth to 6 years, median 1.5 years
  notes: >-
    Marrow failure follows the retinopathy and is the usual cause of death.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients experienced early bone marrow failure, in most cases within the second
      year of life (median age 1.5 years; 95% CI 1.4-1.6).
    explanation: >-
      The reported timing and universality of marrow failure.

- phase: Death in childhood
  age_range: median 6.5 years, none beyond 12 years
  notes: >-
    Survival is the sharpest quantitative difference between this entity and classical
    dyskeratosis congenita, where survival into adulthood is ordinary. Whether that
    difference justifies a separate disease label or simply marks the severe tail of one
    disease is the nosological question this entry does not settle.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Kaplan-Meier estimate of survival was dismal (median survival 6.5 years; 95% CI
      3.6-9.4), and none of the patients survived beyond the age of 12 years.
    explanation: >-
      The survival analysis across all 18 assembled cases.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients died from BMF in most cases, but refractory lung failure was another cause of
      death in some cases.
    explanation: >-
      The reported causes of death, including the pulmonary complication that is the shared
      telomere-disorder endpoint.

pathophysiology:

- name: TINF2 Exon 6 Cluster Variant
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    A heterozygous germline TINF2 variant in a strikingly narrow window: every variant in
    genotyped Revesz patients has fallen in exon 6, between amino acids 280 and 289 of TIN2.
    The recurrent allele is c.845G>A, and the same residue - 282 - accounts for the majority
    of TINF2 dyskeratosis congenita variants generally. Frameshift alleles producing truncated
    TIN2 occur in the same window.

    That window is the "dyskeratosis congenita cluster" of TIN2, and its constancy is the
    single most distinctive genetic fact about this disease. It is also the fact that most
    undermines Revesz as a separate entity: the identical variants are found in patients with
    classical dyskeratosis congenita who never develop the retinopathy. The founding TINF2
    paper makes the point in its own data, reporting R282H across three unrelated probands of
    whom only one had Revesz syndrome. Genotype therefore cannot define this disease, and no
    modifier that does has been identified.
  genes:
  - preferred_term: TINF2
    term:
      id: hgnc:11824
      label: TINF2
  genetic_context:
    gene:
      preferred_term: TINF2
      term:
        id: hgnc:11824
        label: TINF2
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: >-
      Heterozygous germline TINF2 variants confined to exon 6, amino acids 280-289; missense
      substitutions predominate, with frameshift alleles also reported. Almost always de novo.
      No functional_impact_category is recorded: the DC-cluster alleles are neither a clean
      loss of function nor a clean gain, and the two published mechanistic accounts of what
      they do to TIN2 disagree - see the mechanistic hypotheses below.
  downstream:
  - target: Impaired Shelterin-Mediated Telomere Maintenance
    causal_link_type: DIRECT
    description: >-
      TIN2 is a structural hub of shelterin; a variant in its DC cluster impairs the complex's
      maintenance of telomere length. The step is direct, but which molecular activity is lost
      is disputed, so both hypothesis groups attach to the edge below it rather than here.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All of these harbored a TINF2 mutation and the underlying alterations were restricted to
      exon six.
    explanation: >-
      Establishes TINF2 exon 6 as the location of every variant found in genotyped Revesz
      patients.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hence, all mutations were located between amino acid 280 and 289.
    explanation: >-
      The nine-residue window that all reported Revesz alleles fall within.
  - reference: PMID:18252230
    reference_title: "TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrate that a fifth gene, TINF2, is mutated in classical DC and, for the first
      time, in Revesz syndrome.
    explanation: >-
      The paper that first attached TINF2 to this disease, and in the same sentence to
      classical dyskeratosis congenita - the ambiguity the entity has carried ever since.
  - reference: PMID:18669893
    reference_title: "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      A total of 21 of the mutations affected amino acid 282, changing arginine to histidine
      (n = 14) or cysteine (n = 7).
    explanation: >-
      The dominance of residue 282 in a large TINF2 series. INDIRECT for this node because the
      series is TINF2 dyskeratosis congenita broadly rather than Revesz syndrome specifically;
      it establishes the hotspot, not its relation to the Revesz phenotype.

- name: Impaired Shelterin-Mediated Telomere Maintenance
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    Shelterin is the six-protein complex that coats the telomere and suppresses the DNA damage
    response there. TIN2 is its structural hub, binding TRF1 and TRF2 on the duplex telomeric
    DNA and TPP1 - and through TPP1, POT1 - on the single-stranded overhang. A DC-cluster
    variant leaves the complex assembled but impairs its regulation of telomere length.

    What exactly is impaired is genuinely disputed, and the two published accounts are set out
    as separate hypothesis groups rather than blended. One holds that DC-cluster TIN2 mutants
    lose the ability to recruit telomerase; the other, from a knock-in mouse, holds that they
    cause a telomerase-independent replication defect at the telomere. The experiments behind
    each are sound, they are not mutually exclusive, and no work has apportioned them.
  genes:
  - preferred_term: TINF2
    term:
      id: hgnc:11824
      label: TINF2
  protein_complexes:
  - preferred_term: shelterin complex
    term:
      id: GO:0070187
      label: shelterin complex
  biological_processes:
  - preferred_term: telomere maintenance
    term:
      id: GO:0000723
      label: telomere maintenance
    modifier: DECREASED
  cellular_components:
  - preferred_term: telomeric region of the chromosome
    term:
      id: GO:0000781
      label: chromosome, telomeric region
  downstream:
  - target: Extreme Telomere Shortening
    causal_link_type: DIRECT
    hypothesis_groups:
    - tin2_telomerase_recruitment_defect
    description: >-
      Under the recruitment model, the DC-cluster variant reduces TPP1-dependent delivery of
      telomerase to the telomere, so telomeres are not replenished and shorten with every
      division.
  - target: Extreme Telomere Shortening
    causal_link_type: DIRECT
    hypothesis_groups:
    - tin2_telomere_replication_defect
    description: >-
      Under the replication model, the DC-cluster variant makes the telomere a fragile
      replication substrate, producing attrition that persists in the complete absence of
      telomerase.
  evidence:
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It is caused by mutations in the TINF2 gene, which encodes a component of shelterin, a
      six-protein complex that coats the telomere and is essential for suppressing the DNA
      damage response at telomeres
    explanation: >-
      The expert panel's statement of the molecular role of the affected complex.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In RS, mutations in TINF2 at chromosome 14q11.2 result in dysfunctional TIN2 protein
      leading to impaired telomere protection by the shelterin complex
    explanation: >-
      The review's statement of this step as it applies specifically to Revesz syndrome.

- name: Extreme Telomere Shortening
  biological_scale: CELLULAR
  description: >-
    Telomeres far below the first age-adjusted percentile - shorter, as a group, than in any
    other genetic subtype of dyskeratosis congenita. In the assembled Revesz cohort every
    patient with a measurement had a very short result, and in a large TINF2 series the
    telomere lengths were the shortest of all dyskeratosis congenita subtypes while telomerase
    RNA levels were normal, which localises the defect to the telomere rather than to the
    enzyme.

    This is the quantitative link between the genotype and the severity, and the reason
    telomere length by flow-FISH is the functional screening test for the disease. Below some
    threshold, replication-limited tissues stop being replenished; which tissues fail first is
    what the branches below describe.
  biological_processes:
  - preferred_term: replicative senescence
    term:
      id: GO:0090399
      label: replicative senescence
    modifier: INCREASED
  - preferred_term: telomere maintenance via telomerase
    term:
      id: GO:0007004
      label: telomere maintenance via telomerase
    modifier: DECREASED
  downstream:
  - target: Hematopoietic Stem Cell Exhaustion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The best-established branch, shared with all telomere biology disorders: the
      highest-turnover compartment fails first.
  - target: Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The branch that defines this entity, and the one whose intermediates are unknown. No
      study has demonstrated the cellular step between short telomeres and a non-perfused
      peripheral retina.
  - target: Intracranial Calcification and Cerebrovascular Fragility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The CNS branch, equally unresolved at the cellular level.
  - target: Pulmonary Involvement and Respiratory Failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The lung branch, shared with the telomere biology disorders generally, where alveolar
      epithelial replicative failure drives fibrosis. In this disease it matters mainly as a
      cause of death that transplantation does not remove.
  - target: Nail Dystrophy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Revesz syndrome sits inside the dyskeratosis congenita spectrum, and the
      classic mucocutaneous triad is reached by the same route as in DC:
      replicative exhaustion of the high-turnover epithelia. Curated as three
      separate edges because the triad components are three distinct tissues.
  - target: Reticulated Skin Pigmentation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The cutaneous component of the DC triad, in a continuously renewing
      epithelium.
  - target: Oral Leukoplakia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The mucosal component of the DC triad.
  - target: Cerebellar Hypoplasia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Shared with Hoyeraal-Hreidarsson syndrome, the other severe end of the
      telomere biology spectrum. Linked from the telomere node rather than from
      a tissue-exhaustion step because the cerebellum is not a high-turnover
      tissue and the route from telomere shortening to hypoplastic cerebellar
      development is not established.
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The functional counterpart of the structural brain findings. Mechanism
      unestablished, and the contribution of the intracranial calcification and
      haemorrhage curated elsewhere in this entry cannot be separated out.
  - target: Intrauterine Growth Restriction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Prenatal growth failure, consistent with telomere reserve being exhausted
      before birth in the most severe variants. It is the earliest sign that
      this disease is not simply DC with an earlier onset.
  evidence:
  - reference: PMID:18669893
    reference_title: "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Telomere lengths in patients with TINF2 mutations were the shortest compared with other
      DC subtypes, but TERC levels were normal.
    explanation: >-
      Places TINF2 patients at the extreme of telomere shortness among dyskeratosis congenita
      subtypes, with normal telomerase RNA - the observation that makes this a telomere defect
      rather than a telomerase-abundance defect.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Telomere analysis was available in seven patients. All presented with very short lengths
    explanation: >-
      The telomere-length finding in the Revesz cohort itself, in the seven patients who were
      measured.
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Revesz and Hoyeraal-Hreidarsson syndrome are characterized by a severe disease course,
      very short telomeres (considerably below the 1% percentile), and a disease onset in the
      early childhood
    explanation: >-
      A recent review's statement of the telomere threshold that characterises the severe
      pediatric telomere biology disorders, Revesz among them.

- name: Hematopoietic Stem Cell Exhaustion
  biological_scale: TISSUE
  description: >-
    Failure of the marrow's stem cell compartment to sustain haematopoiesis, producing
    progressive pancytopenia in the first years of life. This branch is shared in full with
    classical dyskeratosis congenita and with the other telomere biology disorders; what
    distinguishes Revesz syndrome is only how early it arrives. It is the usual cause of death
    and the target of the only potentially curative treatment.
  cell_types:
  - preferred_term: Hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  downstream:
  - target: Bone Marrow Failure
    causal_link_type: DIRECT
    description: >-
      Exhaustion of the stem cell pool presents clinically as marrow failure.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients experienced early bone marrow failure, in most cases within the second year
      of life (median age 1.5 years; 95% CI 1.4-1.6).
    explanation: >-
      Establishes marrow failure as universal and infantile in this disease.
  - reference: PMID:18669893
    reference_title: "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      A total of 32 of 33 patients with DC with TINF2 mutations have severe disease, with most
      developing aplastic anaemia by the age of 10 years.
    explanation: >-
      The severity and timing of marrow failure across TINF2 dyskeratosis congenita as a whole.
      INDIRECT because the cohort is TINF2 patients generally rather than Revesz patients; it
      shows the early-marrow-failure tendency is a property of the gene, not of the eponym.

- name: Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
  biological_scale: TISSUE
  mechanism_confidence: HYPOTHETICAL
  description: >-
    The lesion that gives the syndrome its name: a bilateral peripheral retinal vasculopathy -
    avascular peripheral retina, telangiectasia, microaneurysms and fluorescein leakage -
    progressing to exudation, neovascularisation, vitreous haemorrhage and tractional retinal
    detachment. Angiographically it is indistinguishable from familial exudative
    vitreoretinopathy, Coats disease and cicatricial retinopathy of prematurity, and children
    with Revesz syndrome have been treated for all three before the systemic diagnosis was made.

    The cellular mechanism is not established. The plausible account is that the retinal
    microvascular endothelium, a slowly renewing compartment, reaches replicative failure at
    the extremely short telomeres these patients carry, so peripheral capillaries drop out and
    the resulting ischaemia drives the exudative and neovascular sequence. No study has
    demonstrated that step - there is no telomere measurement, senescence marker or endothelial
    study in Revesz retina - so the node is tagged HYPOTHETICAL and describes the observed
    vascular lesion rather than the inferred cell biology.

    A 2026 widefield angiography series changed how this node should be read. Peripheral
    non-perfusion was present in 100% of 44 eyes across 22 telomere biology disorder patients,
    most of whom were asymptomatic and none of whom would previously have been called Revesz
    syndrome. On that evidence the retinal branch is not a Revesz-specific limb of the
    pathograph at all; it is a universal telomere-disorder limb that becomes symptomatic
    earliest and most severely in these children.
  cell_types:
  - preferred_term: Retinal microvascular endothelial cell
    term:
      id: CL:0002585
      label: retinal blood vessel endothelial cell
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  downstream:
  - target: Bilateral Exudative Retinopathy
    causal_link_type: DIRECT
    description: >-
      Peripheral capillary dropout and leakage present clinically as exudative retinopathy.
  - target: Retinal Detachment
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Ischaemia drives neovascularisation, vitreous haemorrhage and fibrovascular traction,
      which detach the retina.
  - target: Glaucoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Secondary glaucoma, by the route the same ischaemia takes in other
      proliferative retinopathies: neovascularisation extends onto the iris and
      the drainage angle, obstructing aqueous outflow. Grouped under the
      vasculopathy node rather than treated as an independent ocular
      abnormality for that reason.
  evidence:
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For posterior segment findings, all eyes had some combination of peripheral non-perfusion
      (100%), microaneurysmal changes (63.6%), telangiectasias (54.5%), fluorescein leakage
      (54.5%), sclerotic vessels (40.1%), retinal hemorrhages (36.3%), exudates (27.3%),
      retinal neovascularization (13.6%), and tractional retinal detachment (9.1%).
    explanation: >-
      The best-characterised description of the vascular lesion, quantified by widefield
      fluorescein angiography, and the source for the ordering from non-perfusion through
      leakage to neovascularisation and detachment.
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contrary to prior assumptions, the retinovascular abnormalities in patients with TBDs,
      including DC, were universal in our cohort.
    explanation: >-
      The finding that makes this branch a telomere-disorder feature rather than a
      Revesz-specific one, and the basis for the nosological discussion below.
  - reference: PMID:28095086
    reference_title: "Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Revesz syndrome is a telomere disorder in the dyskeratosis congenita (DKC) spectrum
      characterized by exudative retinopathy, bone marrow failure, neuroradiographic
      abnormalities, and integumentary findings.
    explanation: >-
      A retinal-specialist description of the entity, from the report of identical twins in
      whom the retinopathy was compared directly against the other paediatric retinal
      vasculopathies.
  - reference: PMID:34189343
    reference_title: "Revesz syndrome with bilateral retinal detachments successfully treated by pars plana vitrectomy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were extensive areas of avascular retina detected by fluorescein angiography and a
      thinning of the inner and outer retina detected by optical coherence tomography.
    explanation: >-
      Imaging confirmation of peripheral avascularity in an individual Revesz patient,
      alongside structural retinal thinning.

- name: Intracranial Calcification and Cerebrovascular Fragility
  biological_scale: TISSUE
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Progressive intracranial calcification, most often in the basal ganglia and thalami,
    together with cerebellar hypoplasia and white matter change, and in a minority intracranial
    haemorrhage. Calcification was present in 85% of the Revesz patients imaged and cerebellar
    hypoplasia in 76%.

    The mechanism is inferred rather than shown, and the inference is drawn from a neighbour
    disease. Cerebroretinal microangiopathy with calcifications and cysts - Coats plus, caused
    by CTC1 - produces an almost identical combination of exudative retinopathy and
    intracranial calcification through a small-vessel angiopathy, which is the main reason
    calcification here is read as a microvascular rather than a metabolic process. The
    haemorrhages reported in three Revesz children point the same way. Nothing in the Revesz
    literature demonstrates it: there is no neuropathology series and no vascular study, so
    this node is tagged HYPOTHETICAL and names the imaging finding rather than a cell mechanism.

    Cerebellar hypoplasia is grouped here for anatomical convenience but is probably not the
    same process. It is present from the earliest imaging rather than progressive, which makes
    it a developmental consequence of the telomere defect rather than an acquired vascular one.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Cerebral Calcification
    causal_link_type: DIRECT
  - target: Intracranial Hemorrhage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reported in three of the assembled patients and interpreted by the reviewing authors as
      possible cerebrovascular fragility. The intermediates are unknown and the number is small.
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Attached here because intracranial calcification and haemorrhage are the
      structural lesions in this entry most likely to be epileptogenic. The
      attribution is inference rather than a reported mechanism, and the
      cerebellar and developmental abnormalities curated on the telomere node
      could contribute instead — no cited source separates them.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13)
      were common features
    explanation: >-
      The frequencies of the two neuroimaging findings across the assembled cohort, with their
      denominators.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intracranial hemorrhage was detected in three patients during the course of the disease
    explanation: >-
      The haemorrhage observation that prompted the suggestion of cerebrovascular fragility.
      Three patients is the whole of it.

- name: Pulmonary Involvement and Respiratory Failure
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    Lung disease as the third organ consequence of the telomere defect. Pulmonary fibrosis is a
    well-established feature of the telomere biology disorders as a class - GeneReviews names it
    among the risks of DC/TBD and recommends annual pulmonary function testing from around age
    eight - and its mechanism, replicative failure of the alveolar epithelial progenitor
    compartment, is the same one that empties the marrow.

    What is documented in Revesz syndrome specifically is narrower and more acute: refractory
    lung failure was a cause of death in some of the assembled patients, including after
    transplantation, and the index case died of aspiration pneumonia with refractory lung
    failure. No pulmonary function series, imaging series or histology exists for this disease,
    so the node is tagged PROVISIONAL and is careful not to assert established fibrosis in
    children who mostly die before eight. It is curated because it is a cause of death and
    because it is the branch that survives a successful transplant.
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  biological_processes:
  - preferred_term: replicative senescence
    term:
      id: GO:0090399
      label: replicative senescence
    modifier: INCREASED
  downstream:
  - target: Respiratory Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients died from BMF in most cases, but refractory lung failure was another cause of
      death in some cases.
    explanation: >-
      The only disease-specific evidence for this branch, and the reason it is curated: lung
      failure killed some of these children.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      People with DC/TBD are at increased risk for progressive bone marrow failure (BMF),
      myelodysplastic syndrome or acute myelogenous leukemia, solid tumors (usually squamous
      cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis.
    explanation: >-
      GeneReviews places pulmonary fibrosis among the established risks of the telomere biology
      disorders. INDIRECT because the statement is about DC/TBD as a class, not about Revesz
      syndrome, where fibrosis as such has not been documented.

mechanistic_hypotheses:
- hypothesis_group_id: tin2_telomerase_recruitment_defect
  hypothesis_label: DC-cluster TIN2 variants shorten telomeres by impairing telomerase recruitment
  status: ALTERNATIVE
  description: >-
    Ectopically expressed TIN2 carrying dyskeratosis congenita missense mutations shortens
    telomeres in human cells, and the mutants are specifically defective in associating with
    the telomerase RNA component and with telomerase activity, while leaving total cellular
    telomerase activity, TIN2 localisation and telomere end protection intact. On this account
    the lesion is a failure to deliver telomerase to the telomere through TPP1, not a failure
    of the enzyme or of end protection.

    This is the more widely cited of the two models and fits the clinical observation that
    telomerase RNA levels are normal in TINF2 patients. It is nevertheless recorded as
    ALTERNATIVE rather than CANONICAL, because the mouse work below shows the defect is not
    solely telomerase-dependent, and no experiment has apportioned the two.
  evidence:
  - reference: PMID:21536674
    reference_title: "TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we found TIN2 to participate in the TPP1-dependent recruitment of telomerase activity.
      Furthermore, DC mutations in TIN2 led to its decreased ability to associate with TERC and
      telomerase activity.
    explanation: >-
      The core result of this model: DC-cluster TIN2 mutants lose telomerase association, in a
      pathway TIN2 normally supports through TPP1.
  - reference: PMID:21536674
    reference_title: "TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      However, this telomere shortening was not accompanied by changes in total telomerase
      activity, localization of TIN2, or telomere end protection status.
    explanation: >-
      The controls that make this a recruitment defect specifically rather than a general loss
      of telomerase or of shelterin function.

- hypothesis_group_id: tin2_telomere_replication_defect
  hypothesis_label: DC-cluster TIN2 variants shorten telomeres by a telomerase-independent replication defect
  status: ALTERNATIVE
  description: >-
    A knock-in mouse carrying the equivalent of the TIN2 K280E dyskeratosis congenita allele
    shortens telomeres faster than controls even when telomerase RNA is deleted entirely, which
    is a result the recruitment model cannot produce: if the only defect were telomerase
    delivery, removing telomerase from both genotypes should abolish the difference. The same
    allele induces ATR signalling and a fragile-telomere phenotype, the signature of a
    replication problem at telomeric DNA.

    The authors' own reading is that the two mechanisms compose - a replication defect in
    telomerase-negative somatic tissue on top of impaired telomerase action in stem cell
    compartments - which if correct would explain why so many different tissues fail. Recorded
    as ALTERNATIVE alongside the recruitment model rather than in place of it.
  evidence:
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Unexpectedly, telomere shortening was accelerated in TIN2(+/DC) mTR(-/-) mice and MEFs
      compared with TIN2(+/+) mTR(-/-) controls, establishing that the TIN2(DC) telomere
      maintenance defect was not solely due to diminished telomerase action.
    explanation: >-
      The decisive experiment: the shortening persists and is accelerated with telomerase RNA
      deleted, so it cannot be entirely a telomerase-recruitment failure.
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The TIN2(DC) allele induced mild ATR kinase signaling at telomeres and a fragile telomere
      phenotype, suggestive of telomere replication problems.
    explanation: >-
      The mechanistic signature the authors propose for the telomerase-independent component.

phenotypes:

- category: Ophthalmologic
  name: Bilateral Exudative Retinopathy
  frequency: OBLIGATE
  description: >-
    Bilateral peripheral retinal non-perfusion with exudation, progressing to severe visual
    loss in most patients and to glaucoma in a minority. Present in every reported patient.

    The OBLIGATE frequency is partly circular and should be read that way: retinopathy is one
    of the two features by which the diagnosis is made, so a patient without it would not be
    called Revesz syndrome. The 2026 angiography series makes the circularity explicit -
    retinovascular abnormality is universal across telomere biology disorders once widefield
    angiography is used, so what is obligate here is symptomatic, early, severe retinopathy
    rather than retinal vasculopathy as such.
  phenotype_term:
    preferred_term: Bilateral exudative retinopathy
    term:
      id: HP:0030490
      label: Exudative vitreoretinopathy
    clinical_course: PROGRESSIVE
  diagnostic: true
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RS is a severe variant of DKC with early bone marrow failure and retinopathy in all
      patients.
    explanation: >-
      The review's conclusion that retinopathy was present in all 18 assembled patients.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in
      three cases.
    explanation: >-
      The visual outcome and the frequency of glaucoma as a complication.

- category: Hematologic
  name: Bone Marrow Failure
  frequency: OBLIGATE
  description: >-
    Progressive pancytopenia from failure of the haematopoietic stem cell compartment,
    universal and usually established within the second year of life. It is the usual cause of
    death and the indication for transplantation.
  phenotype_term:
    preferred_term: Bone marrow failure
    term:
      id: HP:0001915
      label: Aplastic anemia
    clinical_course: PROGRESSIVE
  diagnostic: true
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients experienced early bone marrow failure, in most cases within the second year
      of life (median age 1.5 years; 95% CI 1.4-1.6).
    explanation: >-
      Universality and timing of marrow failure across the assembled cohort.

- category: Neurologic
  name: Cerebral Calcification
  frequency: VERY_FREQUENT
  description: >-
    Intracranial calcification, typically in the basal ganglia and thalami and progressive on
    serial imaging. Reported in 11 of the 13 assembled patients with imaging information.
  phenotype_term:
    preferred_term: Intracranial calcification
    term:
      id: HP:0002514
      label: Cerebral calcification
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13)
      were common features
    explanation: >-
      The 85% figure, with its denominator of 13 patients who had the relevant information.
      VERY_FREQUENT is the FrequencyEnum band containing 85%.

- category: Neurologic
  name: Cerebellar Hypoplasia
  frequency: FREQUENT
  description: >-
    Hypoplasia of the cerebellum, with vermian predominance, present on the earliest available
    imaging rather than developing over time. Reported in 13 of 17 assembled patients. It is
    shared with Hoyeraal-Hreidarsson syndrome, where it is a defining feature.
  phenotype_term:
    preferred_term: Cerebellar hypoplasia
    term:
      id: HP:0001321
      label: Cerebellar hypoplasia
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      cerebellar hypoplasia (76%, n = 13/17) and intracranial calcifications (85%, n = 11/13)
      were common features
    explanation: >-
      The 76% figure with its denominator. FREQUENT is the FrequencyEnum band containing 76%.

- category: Neurologic
  name: Global Developmental Delay
  frequency: FREQUENT
  description: >-
    Neurodevelopmental delay or intellectual impairment, present in 12 of 17 assembled patients
    and usually apparent in infancy. The reviewing authors note that deficits were often mild
    and absent in some patients, so cognitive impairment is not an obligate feature.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      this was present in 71% of patients (n = 12/17), frequently emerging during infancy.
    explanation: >-
      The 71% figure and its denominator. FREQUENT is the FrequencyEnum band containing 71%.

- category: Neurologic
  name: Seizures
  frequency: OCCASIONAL
  description: >-
    Seizures in a minority, beginning exclusively in early childhood. The cumulative incidence
    was estimated at 20%, which places this in the OCCASIONAL band and makes it one of the
    features that distinguishes Revesz syndrome from the neurological telomere disorders in
    which seizures are prominent.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of seizures was low and was present in an estimated 20% of patients.
    explanation: >-
      The 20% estimate, which sits in the OCCASIONAL band of 5-29%.

- category: Neurologic
  name: Intracranial Hemorrhage
  frequency: OCCASIONAL
  description: >-
    Spontaneous intracranial haemorrhage in three of the eighteen assembled patients, in at
    least one case with normal blood counts and coagulation at the time, which is why the
    reviewing authors read it as vascular fragility rather than as a consequence of
    thrombocytopenia.
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intracranial hemorrhage was detected in three patients during the course of the disease
    explanation: >-
      Three of eighteen, which places this in the OCCASIONAL band of 5-29%.

- category: Ophthalmologic
  name: Retinal Detachment
  description: >-
    Tractional retinal detachment following neovascularisation and vitreous haemorrhage. No
    frequency is assigned: the retinal-detachment figures available come from eyes in a mixed
    telomere-disorder cohort rather than from Revesz patients, and the individual Revesz
    reports are single cases selected for having been operated on.
  phenotype_term:
    preferred_term: Retinal detachment
    term:
      id: HP:0000541
      label: Retinal detachment
  evidence:
  - reference: PMID:34189343
    reference_title: "Revesz syndrome with bilateral retinal detachments successfully treated by pars plana vitrectomy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 3-year-old Japanese girl with Revesz Syndrome had progressive vitreal hemorrhages and
      tractional retinal detachments in both eyes.
    explanation: >-
      A documented case of bilateral tractional detachment in Revesz syndrome and its
      antecedent vitreous haemorrhage.

- category: Respiratory
  name: Respiratory Failure
  description: >-
    Refractory respiratory failure, reported as a cause of death in some of the assembled
    patients including after transplantation, and the terminal event in the index case following
    aspiration pneumonia. No frequency band is assigned: the source says "some cases" without a
    count, and no pulmonary function or imaging data exist for this disease.

    Pulmonary fibrosis is the mechanism this represents in the telomere biology disorders
    generally, and GeneReviews recommends annual pulmonary function testing from around age
    eight. Whether these children live long enough to develop established fibrosis is not
    documented, so the phenotype is bound to respiratory failure rather than to fibrosis.
  phenotype_term:
    preferred_term: Respiratory failure
    term:
      id: HP:0002878
      label: Respiratory failure
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients died from BMF in most cases, but refractory lung failure was another cause of
      death in some cases.
    explanation: >-
      Records refractory lung failure as a cause of death in this cohort, without a denominator.

- category: Ophthalmologic
  name: Glaucoma
  frequency: OCCASIONAL
  description: >-
    Glaucoma in three of the eighteen assembled patients, a consequence of the neovascular and
    exudative retinal disease rather than an independent finding. It is recorded separately from
    the retinopathy because it is sight-threatening in its own right and needs its own
    monitoring; in the wider telomere-disorder literature neovascular glaucoma has led to
    enucleation.
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in
      three cases.
    explanation: >-
      Three of eighteen, which places this in the OCCASIONAL band of 5-29%, reported alongside
      the visual outcome it follows from.

- category: Integumentary
  name: Nail Dystrophy
  frequency: VERY_FREQUENT
  description: >-
    The most consistently expressed member of the classical dyskeratosis congenita
    mucocutaneous triad in this disease, reported in 13 of 15 patients with information.
  phenotype_term:
    preferred_term: Nail dystrophy
    term:
      id: HP:0008404
      label: Nail dystrophy
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings,
      and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n =
      13/15) of patients with information, respectively.
    explanation: >-
      The 87% figure for nail dystrophy, the third of the three percentages in the sentence.
      VERY_FREQUENT is the band containing 87%.

- category: Integumentary
  name: Reticulated Skin Pigmentation
  frequency: FREQUENT
  description: >-
    Hyperpigmented reticular skin change, reported in 6 of 11 patients with information - less
    consistent than in classical dyskeratosis congenita, probably because these children die
    before the age-dependent mucocutaneous features fully develop.
  phenotype_term:
    preferred_term: Reticulated skin pigmentation
    term:
      id: HP:0007427
      label: Reticulated skin pigmentation
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings,
      and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n =
      13/15) of patients with information, respectively.
    explanation: >-
      The 55% figure for hyperpigmented skin findings, the second of the three percentages.
      FREQUENT is the band containing 55%.

- category: Oral
  name: Oral Leukoplakia
  frequency: FREQUENT
  description: >-
    White mucosal plaques, the least consistently present member of the classical triad here,
    reported in 6 of 14 patients with information. The complete triad was present in only a
    small minority.
  phenotype_term:
    preferred_term: Oral leukoplakia
    term:
      id: HP:0002745
      label: Oral leukoplakia
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      to the classical clinical DKC triad of oral leukoplakia, hyperpigmented skin findings,
      and nail dystrophy were prevalent in only 43% (n = 6/14), 55% (n = 6/11), and 87% (n =
      13/15) of patients with information, respectively.
    explanation: >-
      The 43% figure for oral leukoplakia, the first of the three percentages. FREQUENT is the
      band containing 43%.

- category: Growth
  name: Intrauterine Growth Restriction
  description: >-
    Growth restriction of prenatal onset, or failure to thrive shortly after birth. No
    frequency band is assigned: the review reports growth restriction qualitatively as common
    but not universal, without a single figure that could be banded, and separates preterm
    delivery from small-for-gestational-age status in a way a single percentage would obscure.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Revesz syndrome typically features bilateral exudative retinopathy, intracranial
      calcification, cerebellar hypoplasia thereby causing ataxia, (intrauterine) growth
      restriction, general developmental delay, and fine hairs.
    explanation: >-
      A recent review's feature list for the syndrome, which includes intrauterine growth
      restriction among the typical findings.

- category: Laboratory
  name: Very Short Telomeres
  description: >-
    Leukocyte telomere length far below the first percentile for age, measured by flow-FISH.
    This is the functional screening test for the disease and the biochemical correlate of the
    whole pathograph. Every Revesz patient measured has had a very short result, but only seven
    of the eighteen were measured, so no frequency band is recorded.
  phenotype_term:
    preferred_term: Short telomere length
    term:
      id: HP:0031413
      label: Short telomere length
  diagnostic: true
  reports_on:
  - target: Extreme Telomere Shortening
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Telomere length below the first percentile for age is the measurement of
      this node, and the diagnostic test for the telomere biology disorders.
      Recorded as an observational readout rather than a causal edge: the node
      does not cause the measurement, the measurement reports the node.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Telomere analysis was available in seven patients. All presented with very short lengths
    explanation: >-
      The telomere result in every Revesz patient in whom it was measured, and the denominator
      that measurement rests on.

genetic:

- name: TINF2
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: TINF2
    term:
      id: hgnc:11824
      label: TINF2
  association: >-
    TINF2 encodes TIN2, the structural hub of the shelterin complex. Its link to this disease
    was established in the same 2008 paper that first connected shelterin to human disease at
    all, which reported TINF2 variants in classical dyskeratosis congenita probands and, for
    the first time, in a patient with Revesz syndrome. Every genotyped Revesz patient published
    since 2010 has carried a TINF2 variant in exon 6.

    The gene-disease relationship is not in doubt: ClinGen's Interstitial Lung Disease Gene
    Curation Expert Panel rates TINF2 Definitive, having reached the maximum genetic evidence
    score. What is in doubt is the disease boundary. That same curation applied the ClinGen
    Lumping and Splitting Working Group criteria and lumped Revesz syndrome with autosomal
    dominant dyskeratosis congenita 3, Hoyeraal-Hreidarsson syndrome and pulmonary fibrosis
    into one entity, TINF2-related short telomere syndrome, finding no difference in molecular
    mechanism or inheritance between them.

    The clinical genetics supports that reading rather than contradicting it. The recurrent
    R282H allele appears across probands with classical dyskeratosis congenita, with Revesz
    syndrome and with overlapping presentations, and the Karremann review states plainly that
    genotype alone cannot define Revesz syndrome. No modifier locus, second hit or
    environmental factor explaining who develops the retinal and CNS phenotype has been
    identified.
  evidence:
  - reference: PMID:18252230
    reference_title: "TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrate that a fifth gene, TINF2, is mutated in classical DC and, for the first
      time, in Revesz syndrome.
    explanation: >-
      The founding gene-disease claim for this entity.
  - reference: PMID:18252230
    reference_title: "TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TINF2 R282H in three additional unrelated DC probands, including one with Revesz syndrome
    explanation: >-
      The same allele in three unrelated probands of whom only one had Revesz syndrome - the
      original demonstration, in the founding paper's own data, that the genotype does not
      determine the phenotype.
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TINF2 | HGNC:11824 | dyskeratosis congenita, autosomal dominant 3 | MONDO:0013522 | AD |
      Definitive | SOP11 | Interstitial Lung Disease Gene Curation Expert Panel
    explanation: >-
      The expert-panel classification row. Note the curated disease term is autosomal dominant
      dyskeratosis congenita 3, not Revesz syndrome - there is no Revesz-specific ClinGen
      curation, because the panel folded Revesz into this one.
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, there is definitive evidence to support the relationship between TINF2 and
      TINF2 -related short telomere syndrome.
    explanation: >-
      The panel's conclusion on gene-disease validity, which is what makes relationship_type
      CAUSATIVE here rather than anything weaker.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nevertheless, the same mutations in TINF2 may be found in classical DKC patients
      presenting clinically without the distinct RS phenotype, hence, the genotype alone is not
      able to define RS
    explanation: >-
      The clearest statement that this disease is not genotypically separable from TINF2
      dyskeratosis congenita, from the review that assembled its entire clinical evidence base.

external_assertions:
- name: ClinGen TINF2 gene-disease validity assertion and lumping decision
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
  description: >-
    Recorded because it is two assertions in one, and the second is about this entry's right to
    exist. The ClinGen Interstitial Lung Disease Gene Curation Expert Panel rates TINF2
    Definitive for the disease it curates, approved November 2024 under SOP11. In reaching that
    classification it applied the ClinGen Lumping and Splitting Working Group criteria and
    merged four separately named conditions - autosomal dominant dyskeratosis congenita 3,
    Revesz syndrome, Hoyeraal-Hreidarsson syndrome and pulmonary fibrosis - into a single
    entity, TINF2-related short telomere syndrome, on the ground that no difference in
    molecular mechanism or inheritance pattern separates them.

    dismech does not currently curate that lumped entity, and MONDO, OMIM and Orphanet all
    still carry Revesz syndrome as a distinct concept. This entry therefore curates the MONDO
    term as it exists while recording, prominently, that a criteria-based expert decision has
    already merged it away.
  evidence:
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no
      difference in molecular mechanism or inheritance pattern between these conditions
      suggesting that these may constitute a disease spectrum associated with variants in TINF2 .
    explanation: >-
      The reasoning behind the lumping decision, and the strongest single argument against
      treating Revesz syndrome as a separate disease.
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      have been lumped into one disease entity– TINF2 -related short telomere syndrome.
    explanation: >-
      The decision itself, naming the entity Revesz syndrome was merged into.
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Two forms of DC/TBD with more severe manifestations have been identified, Hoyeraal
      Hreidarsson syndrome, and Revesz syndrome, which were previously thought to be distinct
      disorders, but are now recognized to be part of the phenotypic spectrum of DC
    explanation: >-
      The panel's summary of the current nosological position: distinct disorder previously,
      severity band on dyskeratosis congenita now.

inheritance:
- name: Autosomal dominant, usually de novo
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Heterozygous TINF2 variants, dominant in mechanism but almost never inherited: every
    genetically characterised Revesz patient reported so far has arisen de novo from unaffected
    parents. That is a consequence of the disease rather than a property of the gene - children
    who die before six do not reproduce - and it distinguishes this presentation from TINF2
    dyskeratosis congenita generally, which is transmitted through families.

    No de_novo_rate is recorded. Only twelve of the eighteen assembled patients were genotyped,
    parental testing is not documented for all of them, and a percentage computed on that basis
    would give a precision the source does not have.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast to classical DKC, all cases of RS represented de novo mutations with
      unaffected parents, reflecting the severe course and early death in this disease.
    explanation: >-
      The de novo observation and the review's own explanation of why it follows from the
      severity rather than from the gene.
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TINF2 | HGNC:11824 | dyskeratosis congenita, autosomal dominant 3 | MONDO:0013522 | AD |
      Definitive | SOP11 | Interstitial Lung Disease Gene Curation Expert Panel
    explanation: >-
      The mode of inheritance the expert panel curated the gene under.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Autosomal dominant: NAF1, RPA1, TERC, TINF2, and ZCCHC8.
    explanation: >-
      GeneReviews assigns TINF2 to autosomal dominant transmission within the DC/TBD gene set,
      which is the mode this entry records.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      Once the DC/TBD-related pathogenic variant(s) have been identified in an affected family
      member, prenatal and preimplantation genetic testing are possible.
    explanation: >-
      The reproductive counselling option available once the variant is known. INDIRECT because
      it is written for DC/TBD generally, and because in this disease the variant is almost
      always de novo, so the transmission risk it addresses is a recurrence risk from parental
      gonadal mosaicism rather than from an affected parent.

diagnosis:

- name: Telomere Length Measurement by Flow-FISH
  description: >-
    Age-adjusted lymphocyte telomere length below the first percentile is the functional
    screening test for a telomere biology disorder and is the single most discriminating
    investigation in a child with unexplained exudative retinopathy and cytopenias. Revesz
    patients sit far below that threshold - shorter, as a group, than any other dyskeratosis
    congenita subtype.
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Revesz and Hoyeraal-Hreidarsson syndrome are characterized by a severe disease course,
      very short telomeres (considerably below the 1% percentile), and a disease onset in the
      early childhood
    explanation: >-
      The telomere-length threshold that identifies the severe pediatric telomere biology
      disorders.
  - reference: PMID:18669893
    reference_title: "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Telomere lengths in patients with TINF2 mutations were the shortest compared with other
      DC subtypes, but TERC levels were normal.
    explanation: >-
      Why the test is particularly discriminating for TINF2 disease specifically.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      A majority of individuals with DC/TBD have abnormally short telomeres for their age, as
      determined by multicolor flow cytometry fluorescence in situ hybridization (flow-FISH) on
      lymphocyte subsets.
    explanation: >-
      The GeneReviews statement of the primary diagnostic test for this disease class, naming the
      assay and the tissue. INDIRECT because the chapter covers DC/TBD as a whole; there is no
      Revesz-specific GeneReviews chapter, which is itself consistent with this entry's argument
      that Revesz is not separable from TINF2 dyskeratosis congenita.

- name: Widefield Fluorescein Angiography of the Retina
  description: >-
    Widefield fluorescein angiography demonstrates the peripheral non-perfusion, telangiectasia
    and leakage that define the retinal lesion, and does so before the child is symptomatic.
    The 2026 series that established this found 18 of 22 patients asymptomatic at the time
    their retinal abnormality was detected on screening, which changes the test from a
    confirmatory one into a surveillance one for anybody with a telomere biology disorder.
  evidence:
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 44 eyes from 22 patients were included (59.1% males).
    explanation: >-
      The size of the imaging series behind this recommendation. Small, and the only one of its
      kind.
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Contrary to prior assumptions, the retinovascular abnormalities in patients with TBDs,
      including DC, were universal in our cohort.
    explanation: >-
      The finding that makes angiographic screening worthwhile across telomere biology
      disorders rather than only in children already diagnosed with Revesz syndrome.

- name: TINF2 Sequencing
  description: >-
    Sequencing TINF2, or a telomere biology disorder panel, confirms the molecular diagnosis.
    In this disease the yield is concentrated: every reported variant lies in exon 6.

    A positive result establishes a telomere biology disorder but does not by itself establish
    Revesz syndrome, because the same alleles occur in patients without the retinal and CNS
    phenotype. The diagnosis remains clinical.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All of these harbored a TINF2 mutation and the underlying alterations were restricted to
      exon six.
    explanation: >-
      The concentration of variants in a single exon, which is what makes targeted sequencing
      high-yield here.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nevertheless, the same mutations in TINF2 may be found in classical DKC patients
      presenting clinically without the distinct RS phenotype, hence, the genotype alone is not
      able to define RS
    explanation: >-
      Why a positive TINF2 result is not a diagnosis of this particular entity.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      Pathogenic variants in one of these 16 genes have been identified in approximately 80% of
      individuals who meet clinical diagnostic criteria for DC/TBD.
    explanation: >-
      The diagnostic yield of sequencing across the disease class, and the reason a negative
      panel does not exclude a telomere biology disorder. INDIRECT because the 80% figure is for
      DC/TBD generally; in genotyped Revesz patients the yield has been complete, but on twelve
      patients that is not a comparable statistic.

treatments:

- name: Allogeneic Hematopoietic Stem Cell Transplantation
  therapeutic_modality: CELL_THERAPY
  description: >-
    The only potentially curative treatment for the marrow failure, and the only intervention
    that has demonstrably changed survival in this disease. Eight of the eighteen assembled
    children were transplanted and four were alive at last follow-up, a median of 22 months
    afterwards.

    Conditioning matters more here than in most transplant indications. Alkylators and
    radiation damage the same DNA-repair-limited tissues the disease already compromises, so
    reduced-intensity, radiation-sparing regimens are used; the children in this series who
    received fludarabine, cyclophosphamide and anti-thymocyte globulin tolerated transplant
    without severe early toxicity. Transplantation corrects the haematopoietic branch of the
    pathograph and nothing else: the retinal, pulmonary and CNS branches continue, and
    refractory lung failure remains a cause of death after transplant.
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Hematopoietic Stem Cell Exhaustion
    description: >-
      Replaces the exhausted stem cell compartment with donor cells whose telomeres are of
      normal length. It does not correct the germline defect in any other tissue.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Stem cell transplantation (SCT) was performed in eight children, and after a median of 22
      months from SCT four of these patients were alive at the last follow up visit.
    explanation: >-
      The whole of the transplant outcome data in this disease: eight patients, four alive at a
      median of under two years.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      Patients died from BMF in most cases, but refractory lung failure was another cause of
      death in some cases.
    explanation: >-
      The limit of what transplantation achieves. INDIRECT because the sentence describes causes
      of death across the whole cohort rather than a transplant outcome specifically; it is
      quoted to show the non-haematopoietic branches persist.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      Hematopoietic cell transplantation (HCT) is the only curative treatment for BMF and
      leukemia, but long-term outcome has historically been poor due to treatment toxicity
    explanation: >-
      The GeneReviews management statement for this disease class, which is both the
      justification for transplanting these children and the reason conditioning is chosen the
      way it is. INDIRECT because the chapter addresses DC/TBD as a whole.

- name: Retinal Laser Photocoagulation
  therapeutic_modality: DEVICE
  description: >-
    Ablation of the non-perfused peripheral retina to remove the ischaemic drive to
    neovascularisation. It is the primary ophthalmic treatment proposed in the only systematic
    series of telomere-disorder retinopathy, with anti-VEGF reserved for angiographically
    active eyes.

    The evidence is a case series with a proposed staging system, not a trial, and in the
    assembled Revesz cohort retinopathy still led to severe visual loss in most children
    despite treatment. What laser can plausibly do is preserve some vision if applied before
    the exudative and tractional stages, which is the argument for angiographic screening
    rather than for treating established disease.
  treatment_term:
    preferred_term: laser photocoagulation
    term:
      id: NCIT:C217424
      label: Laser Photocoagulation
  target_mechanisms:
  - target: Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
    description: >-
      Ablates the ischaemic peripheral retina, interrupting the ischaemia-to-neovascularisation
      step. It does not address the telomere defect that produced the non-perfusion.
  evidence:
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We propose a staging system and discuss management strategies, including laser
      photocoagulation as the primary treatment, with adjunctive anti-VEGF agents for vascularly
      active eyes and vitreoretinal surgery for vitreous hemorrhage and retinal detachment.
    explanation: >-
      The management proposal from the largest angiographic series, including the place of laser
      relative to anti-VEGF and surgery.
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      retinopathy led to a severe loss of visual acuity in most patients. Glaucoma occurred in
      three cases.
    explanation: >-
      The visual outcome despite treatment across the assembled cohort. NO_EVIDENCE because the
      sentence reports an outcome in a mixed, uncontrolled group rather than an assessment of
      whether treatment helped; it neither supports nor refutes laser efficacy, and is quoted so
      the treatment is not read as effective on this evidence.

- name: Pars Plana Vitrectomy
  therapeutic_modality: SURGERY
  description: >-
    Vitreoretinal surgery for the end-stage ocular complications - vitreous haemorrhage and
    tractional retinal detachment. Anatomical reattachment with some visual improvement has
    been achieved in individual Revesz patients, in one report after repeated surgery on the
    worse eye, so surgery is worth offering rather than withholding on grounds of prognosis.
    The evidence is single case reports.
  treatment_term:
    preferred_term: vitrectomy
    term:
      id: NCIT:C50837
      label: Vitrectomy
  target_mechanisms:
  - target: Retinal Detachment
    description: >-
      Relieves vitreoretinal traction and clears haemorrhage so the retina can reattach. Purely
      anatomical; the underlying vasculopathy is untouched.
  evidence:
  - reference: PMID:34189343
    reference_title: "Revesz syndrome with bilateral retinal detachments successfully treated by pars plana vitrectomy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A retinal attachment with vision improvement was achieved by a single surgery for the
      right eye and after repeated surgeries for the left eye.
    explanation: >-
      The surgical outcome in the one Revesz patient reported in detail, including that the left
      eye needed repeated surgery.

- name: Multisystem Surveillance and Supportive Care
  therapeutic_modality: OTHER
  description: >-
    Because transplantation corrects only the haematopoietic branch, surveillance of the other
    branches continues afterwards: ophthalmic review, pulmonary assessment, and the hepatic and
    malignancy surveillance that applies across telomere biology disorders. There is no
    Revesz-specific surveillance protocol; the telomere biology disorder guidance applies, which
    for marrow means annual blood counts with bone marrow examination and for the lung means
    annual pulmonary function testing once the child can perform it.

    GeneReviews also lists things to avoid, and two of them matter directly in a disease where
    eight of eighteen published patients were transplanted: non-leukodepleted and non-irradiated
    blood products, and blood donation by family members while transplantation is under
    consideration, since a related donor who is an unrecognised carrier is a real risk when the
    variant is dominant. The androgen plus granulocyte colony-stimulating factor combination is
    also to be avoided because of splenic rupture. That is a distinct claim from androgen
    efficacy, which this entry does not curate.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Extreme Telomere Shortening
    description: >-
      Detects the consequences of the shared upstream defect in each affected organ; it does not
      modify it.
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Revesz syndrome typically features bilateral exudative retinopathy, intracranial
      calcification, cerebellar hypoplasia thereby causing ataxia, (intrauterine) growth
      restriction, general developmental delay, and fine hairs.
    explanation: >-
      The multisystem feature list that determines which specialties surveillance has to cover.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      For BMF: complete blood count (CBC) annually if normal and more often if abnormal; annual
      bone marrow aspirate and biopsy.
    explanation: >-
      The haematological surveillance schedule GeneReviews specifies for this disease class.
      INDIRECT because it is written for DC/TBD generally; in a disease where marrow failure
      arrives at a median of eighteen months, annual counts are a floor rather than a schedule.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      For pulmonary fibrosis: annual pulmonary function tests starting either at diagnosis or
      when the individual can perform the test (often age ~8 years); bubble echocardiogram to
      look for pulmonary arteriovenous malformations if suspected based on clinical symptoms.
    explanation: >-
      The pulmonary surveillance recommendation, and worth reading against this disease's median
      survival of 6.5 years: most of these children never reach the age at which the recommended
      test becomes performable.
  - reference: PMID:20301779
    reference_title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      Agents/circumstances to avoid: Blood donation by family members if HCT is being considered;
      non-leukodepleted and non-irradiated blood products; the combination of androgens and
      granulocyte colony-stimulating factor in treatment of BMF (has been associated with splenic
      rupture); toxic agents implicated in tumorigenesis (e.g., smoking, excessive sun exposure).
    explanation: >-
      The agents and circumstances GeneReviews says to avoid. The first two are directly
      actionable in this disease, where transfusion and transplantation are routine. INDIRECT
      because the list is written for DC/TBD as a class.

clinical_trials:
- name: NCT01659606
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Radiation- and alkylator-free haematopoietic cell transplantation for marrow failure due to
    dyskeratosis congenita and telomere disease. The ClinicalTrials.gov record lists Revesz
    syndrome among its conditions alongside dyskeratosis congenita, Hoyeraal-Hreidarsson
    syndrome and aplastic anaemia. Its premise is exactly the conditioning problem this disease
    poses: DNA-damaging conditioning agents worsen the lung, liver and cancer risk that short
    telomeres already create.
  evidence:
  - reference: clinicaltrials:NCT01659606
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA
      damaging agents in patients with DC, and still have a successful BMT.
    explanation: >-
      The trial's stated hypothesis, which is the rationale behind the reduced-intensity
      conditioning already used in the Revesz patients who were transplanted.

- name: NCT06817590
  phase: PHASE_I
  status: RECRUITING
  description: >-
    Oral nucleoside therapy in telomere biology disorders. The ClinicalTrials.gov record lists
    Revesz syndrome among its conditions. This is the only trial of a systemic,
    mechanism-directed treatment for which patients with this disease are eligible; it is phase
    I, and no efficacy claim should be read into its existence.
  evidence:
  - reference: clinicaltrials:NCT06817590
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC)
      plus deoxythymidine (dT) is safe in patients with telomere biology disorders.
    explanation: >-
      The trial's stated objective and enrolled population, which is the class this disease
      belongs to. Quoted to establish eligibility, not to make any claim about the intervention -
      it is a phase I safety study.

differential_diagnoses:
- name: Hoyeraal-Hreidarsson Syndrome
  description: >-
    The other severe infantile variant of dyskeratosis congenita, and the closest relative.
    Shares cerebellar hypoplasia, intrauterine growth restriction and early marrow failure with
    Revesz syndrome, and was lumped with it into the same TINF2 entity by ClinGen. Distinguished
    clinically by microcephaly, progressive immunodeficiency and more severe cognitive
    impairment, and by the absence of the exudative retinopathy - although proliferative
    retinopathy has been reported in Hoyeraal-Hreidarsson too, which weakens that boundary as
    well.
  distinguishing_features:
  - Microcephaly and progressive immunodeficiency, which are not features of Revesz syndrome.
  - >-
    Not confined to TINF2 - Hoyeraal-Hreidarsson syndrome also arises from RTEL1, TERT, ACD,
    PARN and DKC1 variants.
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Hoyeraal-Hreidarsson syndrome, on the other hand, shares some signs of Revesz syndrome
      such as cerebellar hypoplasia and intrauterine growth restriction, but can also present
      with progressive immunodeficiency, microcephaly, and moderate to severe mental retardation.
    explanation: >-
      The overlap and the distinguishing features, stated side by side by a recent review.

- name: Coats Plus Syndrome
  description: >-
    Cerebroretinal microangiopathy with calcifications and cysts, caused by biallelic CTC1
    variants. It reproduces the Revesz combination of bilateral exudative retinopathy and
    intracranial calcification through a different telomere-maintenance gene, and the two were
    described in the literature as having key similarities before either gene was known.

    It is the most instructive differential in this file, because it shows the Revesz phenotype
    is reachable from a different lesion in the same pathway - which argues that the retinal and
    CNS branches are a property of severe telomere dysfunction rather than of TINF2. dismech
    does not yet curate Coats plus; the two entities should be decided together.
  distinguishing_features:
  - >-
    Autosomal recessive CTC1 variants rather than dominant TINF2, and intracranial cysts and
    leukodystrophy in addition to calcification.
  - >-
    Telomere length is not necessarily reduced, which limits the value of telomere-length
    screening in distinguishing it.
  - >-
    Bone marrow failure, when it occurs, is later - adolescence or early adulthood rather than
    infancy - and gastrointestinal bleeding is prominent.
  evidence:
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Early severe pediatric forms of TBDs with often characteristic underlying genetic variants
      are the Revesz syndrome, the Hoyeraal-Hreidarsson syndrome, and the Coats plus syndrome
    explanation: >-
      Groups the three severe paediatric telomere biology disorders together, which is the
      differential set a clinician faces.

- name: Retinopathy of Prematurity
  description: >-
    Included because it is the misdiagnosis that has actually happened. Revesz syndrome presents
    with bilateral peripheral retinal non-perfusion in an infant, frequently one born preterm or
    small for gestational age, which is precisely the setting in which retinopathy of prematurity
    is expected. At least one child was treated with bilateral laser for presumed retinopathy of
    prematurity before the systemic diagnosis emerged, and others were managed as Coats disease
    or familial exudative vitreoretinopathy.
  distinguishing_features:
  - >-
    Cytopenias, growth restriction and nail or skin change accompanying the retinopathy, none of
    which belong to retinopathy of prematurity.
  - >-
    Progression or new exudative change after the window in which retinopathy of prematurity
    would be expected to stabilise.
  evidence:
  - reference: PMID:35724369
    reference_title: "The Masquerading Retinopathy of Revesz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of a 2-year-old male child, initially treated with bilateral laser
      photocoagulation for retinopathy of prematurity. He developed exudative changes in the
      right eye, presumed to be Coats disease.
    explanation: >-
      A documented case in which Revesz syndrome was treated first as retinopathy of prematurity
      and then as Coats disease before the diagnosis was made.

animal_models:
- name: TIN2(DC) knock-in mouse (K280E equivalent)
  species: Mouse
  genotype: Tinf2 knock-in, equivalent of human TIN2 K280E dyskeratosis congenita allele, heterozygous
  publication: PMID:24449270
  genes:
  - preferred_term: TINF2
    term:
      id: hgnc:11824
      label: TINF2
  description: >-
    A gene-targeted mouse carrying the murine equivalent of TIN2 K280E, a dyskeratosis congenita
    cluster allele that falls inside the same 280-289 window as every reported Revesz variant.
    Homozygotes are inviable; heterozygotes are healthy in the first generation and develop mild
    pancytopenia and reduced fecundity only in the second and third, as bone marrow telomeres
    shorten across generations.

    It is the only in vivo model of a Revesz-window TINF2 allele. It is emphatically not a model
    of Revesz syndrome.
  modeled_mechanisms:
  - target: Extreme Telomere Shortening
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Reproduces the central molecular consequence - progressive telomere attrition from a
      heterozygous DC-cluster TIN2 allele - and reproduces a mild haematopoietic phenotype
      downstream of it. It also produced the finding that the attrition is not solely
      telomerase-dependent, which the human system could not have shown.
    limitations: >-
      Laboratory mice begin with telomeres several times longer than human telomeres, so a
      single generation cannot reach a pathogenic length; the phenotype only appears after
      successive intercrosses, which is a breeding artefact with no human counterpart. The
      haematopoietic phenotype is mild pancytopenia in adult mice rather than the fatal infantile
      marrow failure of this disease. Neither the retinal nor the cerebral branch of the human
      pathograph was assessed - the paper reports no ophthalmic or neuroimaging examination - so
      this model says nothing about the two features that define Revesz syndrome, and its silence
      on them is untested rather than negative.
    readouts:
    - name: Bone marrow telomere length across successive generations
      target: Extreme Telomere Shortening
      direction: DECREASED
      interpretation: >-
        The core readout: telomeres in the haematopoietic compartment shorten progressively over
        generations in heterozygotes, the murine counterpart of the very short telomeres measured
        in patients.
      evidence:
      - reference: PMID:24449270
        reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Bone marrow telomeres of TIN2(+/DC) mice shortened over the generations, and
          immortalized TIN2(+/DC) mouse embryonic fibroblasts (MEFs) showed telomere shortening
          with proliferation.
        explanation: >-
          The telomere measurement in marrow and in fibroblasts that grounds this readout.
    - name: Peripheral blood counts in second- and third-generation heterozygotes
      target: Extreme Telomere Shortening
      direction: DECREASED
      interpretation: >-
        The haematopoietic consequence, and the point at which the model's severity diverges
        sharply from the human disease: mild pancytopenia in later generations of adult mice
        versus universal marrow failure by age six in children.
      evidence:
      - reference: PMID:24449270
        reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In the second and third generations, the TIN2(+/DC) mice developed mild pancytopenia,
          consistent with hematopoietic dysfunction in DC, as well as diminished fecundity.
        explanation: >-
          The blood-count phenotype, and the generation at which it appears.
  evidence:
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we generated mice with the equivalent of the TIN2 K280E DC allele (TIN2(DC)) by gene
      targeting
    explanation: >-
      Establishes the allele modelled, which lies inside the same exon-6 window as every reported
      Revesz variant.
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Whereas homozygous TIN2(DC/DC) mice were not viable, first-generation TIN2(+/DC) mice were
      healthy and fertile.
    explanation: >-
      The generational limitation that governs how this model must be interpreted: a
      first-generation heterozygote is normal.

experimental_models:
- name: Ectopic DC-cluster TIN2 missense expression in human cells
  experimental_model_type: CELL_LINE
  publication: PMID:21536674
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  description: >-
    Human cells expressing TIN2 carrying dyskeratosis congenita cluster missense mutations. The
    system reproduces accelerated telomere shortening and was used to establish what the mutants
    can and cannot do: they lose telomerase association while leaving total telomerase activity,
    TIN2 localisation and telomere end protection intact.
  modeled_mechanisms:
  - target: Impaired Shelterin-Mediated Telomere Maintenance
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the molecular phenotype of a DC-cluster TIN2 allele - progressive telomere
      shortening - in human cells, and localises the defect to telomerase recruitment rather than
      to end protection.
    limitations: >-
      Ectopic overexpression on a wild-type background, not the heterozygous endogenous state of
      a patient; transformed cell lines rather than the stem cell compartments that fail in the
      disease; and a molecular readout with no tissue phenotype. It also cannot address the
      telomerase-independent component that the mouse work later identified, because the system
      retains endogenous telomerase throughout.
    readouts:
    - name: Telomere length in cells expressing DC-mutant TIN2
      target: Impaired Shelterin-Mediated Telomere Maintenance
      direction: DECREASED
      interpretation: >-
        Accelerated telomere shortening, reproducing the patient phenotype in a controlled human
        cell system.
      evidence:
      - reference: PMID:21536674
        reference_title: "TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          ectopic expression of TIN2 with DC missense mutations in human cells led to accelerated
          telomere shortening, similar to the telomere phenotypes found in DC patients
        explanation: >-
          The telomere-length readout and the authors' own comparison of it to the patient
          phenotype.
    - name: Total cellular telomerase activity and telomere end protection status
      target: Impaired Shelterin-Mediated Telomere Maintenance
      direction: UNCHANGED
      interpretation: >-
        A negative result that carries the argument: the shortening is not explained by less
        telomerase or by loss of end protection, which is what narrows the defect to recruitment.
      evidence:
      - reference: PMID:21536674
        reference_title: "TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          However, this telomere shortening was not accompanied by changes in total telomerase
          activity, localization of TIN2, or telomere end protection status.
        explanation: >-
          The three measurements that were unchanged, and the reason the conclusion is specific.

discussions:

- discussion_id: revesz_is_a_severity_band_not_a_disease
  kind: CONTROVERSY
  status: OPEN
  prompt: >-
    Is Revesz syndrome a disease, or a severity band on TINF2 dyskeratosis congenita that two
    authorities have already voted to retire?
  attaches_to:
  - disease#Revesz Syndrome
  - phenotypes#Bilateral Exudative Retinopathy
  - genetic#TINF2
  rationale: >-
    The case for retiring the eponym is strong and comes from two independent directions.
    ClinGen's Interstitial Lung Disease Gene Curation Expert Panel applied the Lumping and
    Splitting Working Group criteria in 2024 and merged Revesz syndrome into TINF2-related short
    telomere syndrome, finding no difference in molecular mechanism or inheritance from classical
    dyskeratosis congenita. Independently, a 2026 widefield angiography series found
    retinovascular abnormality in every eye of every telomere biology disorder patient examined,
    most of them asymptomatic, and proposed replacing the eponym with Short Telomere Associated
    Retinopathy. Add the Karremann review's finding that genotype cannot define the syndrome, and
    the entity has no mechanistic, genetic or now even phenotypic boundary.

    The case for keeping a record is narrower but real. The natural history is categorically
    different - median survival 6.5 years against survival into adulthood in classical
    dyskeratosis congenita - and the retinal and cerebral branches of the pathograph are absent
    from the dismech Dyskeratosis Congenita entry, whose subtype list is keyed by gene and whose
    Subtype records cannot hold pathophysiology in any case. MONDO, OMIM and Orphanet all still
    carry the term, so a clinician or a pipeline will keep encountering it.

    This entry takes the position that curating the concept with the dispute attached is more
    useful than deleting it: a reader who arrives at MONDO:0009990 should find the lumping
    decision and the STAR proposal, not silence. If dismech later curates TINF2-related short
    telomere syndrome as an entity, this file should be reconsidered as a subtype of it.
  evidence:
  - reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
    reference_title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no
      difference in molecular mechanism or inheritance pattern between these conditions
      suggesting that these may constitute a disease spectrum associated with variants in TINF2 .
    explanation: >-
      The formal, criteria-based decision against Revesz syndrome being a separate entity. REFUTE
      relative to the claim that this is a distinct disease.
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with retinopathy have been termed Revesz syndrome until now, but with the advent
      of WF-FA, we show that the retinopathy is likely more prevalent than previously thought.
    explanation: >-
      The ophthalmological argument against the eponym: the feature that defines it is not
      distinctive once imaged properly.
  - reference: PMID:42617951
    reference_title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We propose that these findings be termed Short Telomere Associated Retinopathy (STAR) to
      reflect the underlying systemic pathophysiology.
    explanation: >-
      The proposed replacement terminology, named here so the concept is findable under both.
  - reference: PMID:39371255
    reference_title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      certain pediatric forms such as the Revesz syndrome, the Hoyeraal-Hreidarsson syndrome, or
      the Coats plus syndrome are characterized by a strikingly more severe phenotype and earlier
      disease onset clearly distinct from classical DKC
    explanation: >-
      The counter-position, from a 2024 review: the severe paediatric forms are clinically
      distinct from classical dyskeratosis congenita. Note this is a phenotype description rather
      than a nosological ruling, so it is weaker in kind than the ClinGen decision it opposes.

- discussion_id: revesz_tissue_selectivity_gap
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why do the retina and the cerebral microvasculature fail catastrophically in these children
    when other carriers of the identical TINF2 variant develop classical dyskeratosis congenita?
  attaches_to:
  - pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
  - pathophysiology#Intracranial Calcification and Cerebrovascular Fragility
  - pathophysiology#TINF2 Exon 6 Cluster Variant
  rationale: >-
    This is the central unexplained fact of the disease. R282H appears in unrelated probands with
    classical dyskeratosis congenita, with Revesz syndrome, and with overlapping presentations,
    and the review that assembled the cohort states that genotype alone cannot define the
    syndrome. Something other than the TINF2 allele determines whether a child develops
    sight-destroying retinopathy and intracranial calcification in infancy.

    No candidate has been tested. Parentally inherited telomere length, a modifier locus, a
    second variant, and stochastic variation in how short telomeres are at conception are all
    plausible and none has been examined in a Revesz cohort - which, at eighteen patients across
    the whole literature, may be too small to examine any of them. The STAR finding partially
    dissolves the question for the retina by making retinopathy universal, but it does not touch
    the CNS branch, and it does not explain the difference in severity and age of onset.
  evidence:
  - reference: PMID:33097095
    reference_title: "Revesz syndrome revisited."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nevertheless, the same mutations in TINF2 may be found in classical DKC patients presenting
      clinically without the distinct RS phenotype, hence, the genotype alone is not able to
      define RS
    explanation: >-
      The statement of the gap: identical genotype, different disease.
  proposed_experiments:
  - experiment_id: revesz_modifier_and_telomere_setpoint
    name: Parental telomere-length and modifier analysis across TINF2 carriers stratified by ocular phenotype
    description: >-
      Assemble TINF2 exon-6 carriers with and without early exudative retinopathy, measure
      telomere length in the probands and both parents, and sequence for modifier variants in
      telomere-maintenance and retinal-vascular genes. The design tests whether the Revesz
      phenotype tracks a shorter inherited telomere set point rather than a distinct lesion.
    would_support:
    - pathophysiology#Extreme Telomere Shortening
    supporting_outcome:
    - >-
      Carriers with the Revesz phenotype have shorter telomeres, or shorter parental telomeres,
      than genotype-matched carriers without it, in a dose-dependent relation to age of ocular
      onset.
    would_refute:
    - pathophysiology#Extreme Telomere Shortening
    refuting_outcome:
    - >-
      Telomere length is indistinguishable between carriers with and without the Revesz
      phenotype, which would place the determinant outside telomere length altogether.
  - experiment_id: revesz_retinal_endothelial_senescence
    name: Senescence and telomere phenotyping of retinal microvascular endothelium in telomere biology disorders
    description: >-
      Measure telomere length and senescence markers in retinal microvascular endothelial cells -
      from donor eyes, or from patient iPSC-derived retinal microvascular endothelium - and
      compare against a matched non-retinal endothelial bed, to test whether the retinal
      periphery is intrinsically more vulnerable to short telomeres than other vascular beds.
    would_support:
    - pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
    supporting_outcome:
    - >-
      Retinal microvascular endothelium shows shorter telomeres and higher senescence-marker
      burden than the comparator bed in the same patients, with peripheral retina worse than
      posterior pole.
    would_refute:
    - pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
    refuting_outcome:
    - >-
      No difference in telomere length or senescence between retinal and comparator endothelium,
      which would make peripheral non-perfusion a consequence of something other than endothelial
      replicative failure.

- discussion_id: tin2_dc_mechanism_dispute
  kind: OPEN_QUESTION
  status: OPEN
  prompt: >-
    Do DC-cluster TIN2 variants shorten telomeres by failing to recruit telomerase, by causing a
    telomerase-independent replication defect, or by both?
  attaches_to:
  - pathophysiology#Impaired Shelterin-Mediated Telomere Maintenance
  - mechanistic_hypotheses#tin2_telomerase_recruitment_defect
  - mechanistic_hypotheses#tin2_telomere_replication_defect
  rationale: >-
    Two well-executed studies reach different answers, and the disagreement is real rather than
    apparent. Human-cell work shows DC-cluster TIN2 mutants losing telomerase association while
    end protection is intact, which is a recruitment defect. Mouse knock-in work shows the same
    class of allele accelerating telomere shortening with telomerase RNA deleted entirely, which
    a recruitment defect cannot produce, together with ATR signalling and fragile telomeres.

    The most likely resolution is that both operate, in different compartments - recruitment
    failure in telomerase-positive stem cells, replication failure in telomerase-negative somatic
    tissue - which is what the mouse authors themselves propose. If that is right it has a
    consequence for this disease specifically: a replication defect in telomerase-negative tissue
    would predict damage in slowly renewing compartments such as retinal endothelium, which is
    exactly where this syndrome differs from classical marrow-limited disease. Nobody has tested
    that prediction.
  evidence:
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These data suggest that this TIN2-DC mutation could induce telomeric dysfunction phenotypes
      in telomerase-negative somatic cells and tissues that further exacerbate the telomere
      maintenance problems in telomerase-positive stem cell compartments.
    explanation: >-
      The authors' own proposed reconciliation of the two mechanisms, and the source of the
      testable prediction about slowly renewing tissue.

- discussion_id: revesz_mouse_model_mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Can any current model reproduce the retinal and CNS phenotypes that define Revesz syndrome?
  attaches_to:
  - animal_models#Mouse
  - pathophysiology#Retinal Peripheral Non-Perfusion and Exudative Vasculopathy
  rationale: >-
    The only in vivo model of a Revesz-window TINF2 allele is the TIN2(DC) knock-in mouse, and it
    models the wrong part of the disease. Its phenotype is mild pancytopenia appearing only in the
    second and third generations, because laboratory mice start with far longer telomeres than
    humans; first-generation heterozygotes are healthy and fertile. No ophthalmic or neuroimaging
    assessment is reported, so the model is silent rather than negative on the retinal and CNS
    branches.

    This is a HUMAN_MODEL_MISMATCH rather than a plain gap because a model does exist and is
    informative - it produced the telomerase-independent finding that the human system could not
    have - while being structurally unable to address the features that define the disease. Any
    model that could would need a short-telomere background, such as a late-generation
    telomerase-null mouse, or a human iPSC-derived retinal vascular system.
  evidence:
  - reference: PMID:24449270
    reference_title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Whereas homozygous TIN2(DC/DC) mice were not viable, first-generation TIN2(+/DC) mice were
      healthy and fertile.
    explanation: >-
      The generational limitation that makes this model a poor match for an infantile human
      disease.

notes: >-
  **The lump-or-split decision, and how it was reached.** The stub was recorded as a Disease and
  curated as a standalone entry, against a genuinely strong case for making it a subtype. The
  deciding argument was structural rather than biological. Biologically, the case for a subtype is
  better: Revesz has no upstream mechanistic divergence from TINF2 dyskeratosis congenita at all -
  it is the same gene, the same exon, often the same allele, and the same shelterin defect - which
  is precisely the divergence that justified a standalone entry for methylmalonic aciduria cblA in
  issue #10260. ClinGen's Lumping and Splitting Working Group reached the same conclusion formally
  in 2024 and merged the concept away.

  What decided it the other way is what a subtype record can hold. The dismech Dyskeratosis
  Congenita pathograph has three nodes and terminates in marrow, lung and liver; it has no retinal
  and no CNS branch, and its has_subtypes list is keyed by gene, so Revesz - which is not a gene,
  and whose alleles also produce non-Revesz disease - has no axis to sit on. More decisively, the
  Subtype class in this schema carries name, term, mappings, description, evidence, genes,
  frequency and inheritance and nothing else: no pathophysiology, no progression, no treatments, no
  models, no discussions. Recording Revesz as a subtype would have bound MONDO:0009990 and
  discarded the retinal and cerebral limbs of the pathograph, the two competing TIN2 mechanisms,
  the natural history, the transplant outcomes, and the STAR reframing - which is the material this
  file exists to preserve. That is the same shape of argument the cblA PR made about its umbrella's
  subtype axis, applied to a different limitation.

  Dyskeratosis_Congenita.yaml was not modified. It still describes Revesz in its top-level prose,
  in its TINF2 subtype description, and as an unattached Exudative retinopathy phenotype, and it
  still binds no MONDO term for it. That duplication is deliberate and follows the cblA precedent
  of leaving the umbrella alone.

  **Named entity confusion.** The gene is not the trap here - TINF2 is uncontested and preflight-dr
  passed cleanly with 52 TINF2 mentions and the correct OMIM. The trap is the neighbouring
  syndromes, which share the retinopathy, the calcification, or both: Coats plus / cerebroretinal
  microangiopathy (CTC1), Hoyeraal-Hreidarsson syndrome, and the growing literature on
  telomere-disorder retinopathy in TERT, RTEL1 and TERC patients. Every clinical citation in this
  file was checked to be about patients labelled Revesz syndrome, with two deliberate exceptions
  that are marked as such: the Walne TINF2 series and the STAR angiography series are about broader
  telomere-disorder cohorts, and each is used with directness INDIRECT or with an explanation
  saying what population it describes. A TINF2 autopsy study of tissue-specific telomere shortening
  was read and excluded, because its patient had classical dyskeratosis congenita and survived to
  eighteen.

  **What was deliberately not curated.** No biochemical, histopathology, imaging_findings or
  dataset sections: there is no neuropathology series, no biomarker panel and no omics dataset for
  this disease, and populating those from telomere-disorder sources generally would manufacture
  depth that does not exist. No frequency band on intrauterine growth restriction, retinal
  detachment, respiratory failure or short telomeres, because in each case the available number
  comes from the wrong denominator or there is none. No androgen or nucleoside pharmacotherapy
  treatment entry: danazol response data come from adult telomere-disorder cohorts and there is no
  Revesz evidence, so the nucleoside trial is recorded under clinical_trials as eligibility rather
  than as treatment. Note this is separate from the GeneReviews warning against combining androgens
  with G-CSF, which is a safety statement rather than an efficacy claim and is recorded on the
  surveillance entry.

  Somatic reversion in TINF2 disease - which can make blood-derived DNA misleading and is a real
  false-negative mode for sequencing - is not curated. It is a genuine gap rather than a judgement
  call: the deep-research report raises it, but none of the references cached for this entry,
  GeneReviews included, contains a quotable sentence stating it, and this entry does not assert
  claims it cannot quote.

  **Related queue items**, none of them addressed in this PR. stubs/Coats_Plus_Syndrome.yaml is
  open, already decided as entry_type DISEASE, and covers the disease with the most nearly
  identical pathograph to this one - exudative retinopathy plus intracranial calcification,
  reached through CTC1 instead of TINF2. The two should ideally be decided by the same curator.
  stubs/Dyskeratosis_Congenita_Autosomal_Dominant_3.yaml carries MONDO:0013522, which is the term
  ClinGen curated when it lumped Revesz syndrome away; if that stub is curated, this file should
  be revisited as a subtype of it. Hoyeraal-Hreidarsson syndrome is in the position Revesz was in -
  described in the Dyskeratosis Congenita entry, bound nowhere - and appears in the queue only as
  a synonym and mondo_descendant on stubs/Dyskeratosis_Congenita_X-linked.yaml. That placement
  follows MONDO, which nests MONDO:0018045 under the X-linked term, but it understates the
  concept's scope: Hoyeraal-Hreidarsson syndrome is not confined to DKC1 and occurs with RTEL1,
  TERT, ACD, PARN and TINF2 variants.

references:
- reference: PMID:33097095
  title: "Revesz syndrome revisited."
- reference: PMID:18252230
  title: "TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita."
- reference: PMID:18669893
  title: "TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes."
- reference: PMID:42617951
  title: "Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR)."
- reference: PMID:39371255
  title: "Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment."
- reference: PMID:21536674
  title: "TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase."
- reference: PMID:24449270
  title: "A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice."
- reference: PMID:28095086
  title: "Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies."
- reference: PMID:34189343
  title: "Revesz syndrome with bilateral retinal detachments successfully treated by pars plana vitrectomy."
- reference: PMID:35724369
  title: "The Masquerading Retinopathy of Revesz Syndrome."
- reference: PMID:20301779
  title: "Dyskeratosis Congenita and Related Telomere Biology Disorders."
  tags:
  - GeneReviews
- reference: CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z
  title: "TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)"
- reference: clinicaltrials:NCT01659606
  title: "Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease"
- reference: clinicaltrials:NCT06817590
  title: "Nucleoside Therapy in Patients With Telomere Biology Disorders"

📚

References & Deep Research

References

14

PMID:33097095

Revesz syndrome revisited.

No top-level findings curated for this source.

PMID:18252230

TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.

No top-level findings curated for this source.

PMID:18669893

TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.

No top-level findings curated for this source.

PMID:42617951

Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR).

No top-level findings curated for this source.

PMID:39371255

Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment.

No top-level findings curated for this source.

PMID:21536674

TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase.

No top-level findings curated for this source.

PMID:24449270

A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice.

No top-level findings curated for this source.

PMID:28095086

Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies.

No top-level findings curated for this source.

PMID:34189343

Revesz syndrome with bilateral retinal detachments successfully treated by pars plana vitrectomy.

No top-level findings curated for this source.

PMID:35724369

The Masquerading Retinopathy of Revesz Syndrome.

No top-level findings curated for this source.

PMID:20301779

Dyskeratosis Congenita and Related Telomere Biology Disorders.

No top-level findings curated for this source.

CGGV:assertion_b32866f2-6fa1-4a63-9624-3588d0811ea7-2025-02-20T170000.000Z

TINF2 / dyskeratosis congenita, autosomal dominant 3 (Definitive)

No top-level findings curated for this source.

clinicaltrials:NCT01659606

Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease

No top-level findings curated for this source.

clinicaltrials:NCT06817590

Nucleoside Therapy in Patients With Telomere Biology Disorders

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

**The lump-or-split decision, and how it was reached.** The stub was recorded as a Disease and curated as a standalone entry, against a genuinely strong case for making it a subtype. The deciding argument was structural rather than biological. Biologically, the case for a subtype is better: Revesz has no upstream mechanistic divergence from TINF2 dyskeratosis congenita at all - it is the same gene, the same exon, often the same allele, and the same shelterin defect - which is precisely the divergence that justified a standalone entry for methylmalonic aciduria cblA in issue #10260. ClinGen's Lumping and Splitting Working Group reached the same conclusion formally in 2024 and merged the concept away. What decided it the other way is what a subtype record can hold. The dismech Dyskeratosis Congenita pathograph has three nodes and terminates in marrow, lung and liver; it has no retinal and no CNS branch, and its has_subtypes list is keyed by gene, so Revesz - which is not a gene, and whose alleles also produce non-Revesz disease - has no axis to sit on. More decisively, the Subtype class in this schema carries name, term, mappings, description, evidence, genes, frequency and inheritance and nothing else: no pathophysiology, no progression, no treatments, no models, no discussions. Recording Revesz as a subtype would have bound MONDO:0009990 and discarded the retinal and cerebral limbs of the pathograph, the two competing TIN2 mechanisms, the natural history, the transplant outcomes, and the STAR reframing - which is the material this file exists to preserve. That is the same shape of argument the cblA PR made about its umbrella's subtype axis, applied to a different limitation. Dyskeratosis_Congenita.yaml was not modified. It still describes Revesz in its top-level prose, in its TINF2 subtype description, and as an unattached Exudative retinopathy phenotype, and it still binds no MONDO term for it. That duplication is deliberate and follows the cblA precedent of leaving the umbrella alone. **Named entity confusion.** The gene is not the trap here - TINF2 is uncontested and preflight-dr passed cleanly with 52 TINF2 mentions and the correct OMIM. The trap is the neighbouring syndromes, which share the retinopathy, the calcification, or both: Coats plus / cerebroretinal microangiopathy (CTC1), Hoyeraal-Hreidarsson syndrome, and the growing literature on telomere-disorder retinopathy in TERT, RTEL1 and TERC patients. Every clinical citation in this file was checked to be about patients labelled Revesz syndrome, with two deliberate exceptions that are marked as such: the Walne TINF2 series and the STAR angiography series are about broader telomere-disorder cohorts, and each is used with directness INDIRECT or with an explanation saying what population it describes. A TINF2 autopsy study of tissue-specific telomere shortening was read and excluded, because its patient had classical dyskeratosis congenita and survived to eighteen. **What was deliberately not curated.** No biochemical, histopathology, imaging_findings or dataset sections: there is no neuropathology series, no biomarker panel and no omics dataset for this disease, and populating those from telomere-disorder sources generally would manufacture depth that does not exist. No frequency band on intrauterine growth restriction, retinal detachment, respiratory failure or short telomeres, because in each case the available number comes from the wrong denominator or there is none. No androgen or nucleoside pharmacotherapy treatment entry: danazol response data come from adult telomere-disorder cohorts and there is no Revesz evidence, so the nucleoside trial is recorded under clinical_trials as eligibility rather than as treatment. Note this is separate from the GeneReviews warning against combining androgens with G-CSF, which is a safety statement rather than an efficacy claim and is recorded on the surveillance entry. Somatic reversion in TINF2 disease - which can make blood-derived DNA misleading and is a real false-negative mode for sequencing - is not curated. It is a genuine gap rather than a judgement call: the deep-research report raises it, but none of the references cached for this entry, GeneReviews included, contains a quotable sentence stating it, and this entry does not assert claims it cannot quote. **Related queue items**, none of them addressed in this PR. stubs/Coats_Plus_Syndrome.yaml is open, already decided as entry_type DISEASE, and covers the disease with the most nearly identical pathograph to this one - exudative retinopathy plus intracranial calcification, reached through CTC1 instead of TINF2. The two should ideally be decided by the same curator. stubs/Dyskeratosis_Congenita_Autosomal_Dominant_3.yaml carries MONDO:0013522, which is the term ClinGen curated when it lumped Revesz syndrome away; if that stub is curated, this file should be revisited as a subtype of it. Hoyeraal-Hreidarsson syndrome is in the position Revesz was in - described in the Dyskeratosis Congenita entry, bound nowhere - and appears in the queue only as a synonym and mondo_descendant on stubs/Dyskeratosis_Congenita_X-linked.yaml. That placement follows MONDO, which nests MONDO:0018045 under the X-linked term, but it understates the concept's scope: Hoyeraal-Hreidarsson syndrome is not confined to DKC1 and occurs with RTEL1, TERT, ACD, PARN and TINF2 variants.

Address ai4c-reviewer findings on PR #10328: GeneReviews baseline and the unmodeled pulmonary branch · 2026-09-01T02:08:07Z · View source

Response to the automated review on PR #10328. Both blocking findings were checked against the cached source before acting; both were correct and both are fixed. Finding 1, the GeneReviews baseline. references_cache/PMID_20301779.md - Savage and Niewisch, Dyskeratosis Congenita and Related Telomere Biology Disorders - was already committed in the repository, names Revesz syndrome explicitly, and was neither tagged nor cited. The reviewer's point that this is not a box-check is the right one: there is no Revesz-specific GeneReviews chapter, and this entry's own argument is that Revesz is not separable from TINF2 dyskeratosis congenita, which makes the DC/TBD chapter the authoritative clinical source for it. It is now tagged GeneReviews in the references block and cited across all four required domains: flow-FISH on the telomere-length diagnosis entry, the 80% sequencing yield on the TINF2 sequencing entry, the HCT-is-the-only-curative-treatment statement on the transplantation entry, the marrow and pulmonary surveillance schedules and the agents-to-avoid list on the surveillance entry, and the autosomal-dominant gene assignment plus the prenatal/preimplantation testing statement on the inheritance block. Every one is marked directness INDIRECT with an explanation naming the population, because the chapter is written for DC/TBD as a class. Finding 2, the pulmonary branch. The reviewer is right that the entry quoted refractory lung failure twice and referred in notes to a pulmonary branch that did not exist. Added a fourth downstream edge from Extreme Telomere Shortening to a new pathophysiology node, Pulmonary Involvement and Respiratory Failure, plus a Respiratory Failure phenotype bound to HP:0002878. The node is deliberately not called pulmonary fibrosis and the phenotype is not bound to HP:0002206. Fibrosis is the established telomere-disorder mechanism and GeneReviews names it, but what is documented in Revesz syndrome is acute refractory lung failure as a cause of death, including after transplantation; no pulmonary function series, imaging or histology exists for this disease, and most of these children die before the age at which GeneReviews says pulmonary function testing becomes performable. Binding to fibrosis would have asserted a lesion nobody has demonstrated in a Revesz patient. The node carries mechanism_confidence PROVISIONAL and says this. No frequency band, because the source says some cases without a count. Suggestion 3 accepted: Glaucoma is now its own Ophthalmologic phenotype, HP:0000501, banded OCCASIONAL on three of eighteen, rather than living inside the retinopathy prose. Suggestion 4 accepted and folded into finding 1: the GeneReviews agents-to-avoid list is on the surveillance treatment, with the two items that matter most in this disease called out - non-leukodepleted and non-irradiated blood products, and blood donation by family members while transplantation is under consideration, which matters because a related donor may be an unrecognised carrier of a dominant variant. The androgen plus G-CSF warning is included and the notes now say explicitly that a safety warning is a different claim from the danazol efficacy data this entry still declines to curate. Suggestion 5 declined, with the reason recorded in notes rather than left silent: somatic reversion in TINF2 disease is a real false-negative mode for blood-derived sequencing, and the deep-research report raises it, but no reference cached for this entry - GeneReviews included - contains a quotable sentence stating it. It is recorded in notes as a known gap. Validation after the changes: just validate, validate-terms, check-entity-refs, check-duplicate-keys and validate-disorders all exit 0; 93 of 93 snippets verified against the cached references, up from 81. All five whole-KB gates exit 0, and the entity-ref, conforms_to and causal-target pytest lanes pass.

Falcon ▸

Revesz Syndrome: Comprehensive Disease-Characteristics Report

Edison Scientific Literature 38 citations 2026-08-31T17:52:58.939798

Revesz Syndrome: Comprehensive Disease-Characteristics Report

Target entity: Revesz syndrome (RS), a severe, early-onset telomere biology disorder (TBD), usually caused by heterozygous pathogenic TINF2 variants and characterized by early bone-marrow failure, bilateral exudative retinopathy, and intracranial abnormalities.

Evidence boundary. RS is exceptionally rare. The strongest RS-specific quantitative source remains the systematic review of 18 children published by Karremann et al. on 7 October 2020 (DOI: 10.1186/s13023-020-01553-y). No 2023–2024 RS-specific cohort superseding it was identified. Consequently, this report labels recommendations derived from the broader DC/TBD literature as TBD extrapolation, rather than presenting them as demonstrated RS evidence. The underlying data are aggregated disease-level literature and case reports, not individual-level EHR data. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)

The following table provides a knowledge-base-oriented synopsis.

Domain	Best-supported finding	Quantitative detail	Evidence type	Knowledge-base ontology suggestions
Disease identifiers	Revesz syndrome is an ultra-rare, severe pediatric telomere biology disorder within the dyskeratosis congenita spectrum, classically defined by bilateral exudative retinopathy plus intracranial calcification/cerebellar hypoplasia and early bone marrow failure; OMIM #268130 and MONDO:0009990 are supported in retrieved sources	18 children summarized in the largest RS-specific review; all pediatric cases (karremann2020reveszsyndromerevisited pages 1-2, karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 8-9, OpenTargets Search: Revesz syndrome-TINF2)	RS-specific systematic review + broader TBD review	MONDO:0009990; MeSH: Dyskeratosis Congenita; HPO: HP:0001872 Pancytopenia, HP:0000510 Blindness, HP:0009713 Nail dystrophy
Synonyms / nomenclature	RS is best treated as a disease-level, aggregated literature-defined syndrome; recent sources also describe it as an early severe pediatric TBD and a TINF2-associated dyskeratosis congenita variant	No EHR-derived cohort identified; evidence comes from published case reports/reviews (karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)	RS-specific + broader TBD extrapolation	MONDO label plus exact synonym string: TINF2-associated dyskeratosis congenita with bilateral exudative retinopathy and intracranial calcification
Epidemiology / demographics	Extremely rare; no population prevalence or incidence was identified. Reported sex distribution does not support strong male predominance	18 cases total; 7 female, 11 male; median survival 6.5 years; none survived beyond 12 years in the 2020 review (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)	RS-specific systematic review	HANCESTRO/NCIT demographic annotations as available; evidence gap flag for prevalence/incidence
Inheritance	RS is usually caused by de novo heterozygous TINF2 variants, although TINF2-related TBDs more broadly can also show autosomal dominant familial inheritance and anticipation	In reviewed RS cases, all genetically characterized patients reportedly had unaffected parents/de novo events; TINF2 often de novo in broader TBDs (karremann2020reveszsyndromerevisited pages 7-8, savage2022dyskeratosiscongenitaand pages 8-10, rolles2024inheritedtelomerebiology pages 2-4)	RS-specific + broader TBD extrapolation	HP:0000006 Autosomal dominant inheritance; HP:0032113 De novo mutation
Causal gene	TINF2 is the established causal gene for RS	Open Targets shows Revesz syndrome–TINF2 association; evidence size 5 (OpenTargets Search: Revesz syndrome-TINF2)	Disease-target association + RS review	HGNC: TINF2; NCBI Gene: TINF2; GO CC: shelterin complex
Pathogenic variants	RS-associated variants cluster in TINF2 exon 6, especially around amino acids 280-289; p.Arg282His is the most recurrent hotspot. Truncating variants can also produce severe early phenotypes including RS	In historical TINF2-DC series, c.845G>A (p.Arg282His) accounted for 12 DC, 2 DC/RS, 1 DC/HH/RS probands; RS also reported with c.839delA (p.Lys280Argfs*36); mosaic c.865C>T (p.Pro289Ser) reported in an RS case (sasa2012threenoveltruncating pages 3-4, tomcikova2018whyisit pages 1-2, karremann2020reveszsyndromerevisited pages 7-8)	RS-specific cases + TINF2 variant series	HGVS variant annotations; SO:0001583 missense_variant, SO:0001589 frameshift_variant, SO:0001587 stop_gained
Telomere biomarker	Very short telomeres are a defining functional biomarker in RS and early severe TBDs	In 7 RS patients with measurements, telomeres were below the 1st percentile for age; example RS case telomeres 2.47-2.48 kb (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 4-7, rolles2024inheritedtelomerebiology pages 8-9)	RS-specific review/case + broader TBD review	HPO: HP:0034004 Short telomere; LOINC/assay annotation for flow-FISH telomere length
Core phenotype: bone marrow failure	Early bone marrow failure is universal or near-universal in RS and often the dominant life-limiting manifestation	All reviewed patients had early BMF; onset median 1.5 years, within second year; all by age 6 years (karremann2020reveszsyndromerevisited pages 1-2, karremann2020reveszsyndromerevisited pages 7-8)	RS-specific systematic review	HPO: HP:0001876 Pancytopenia, HP:0005528 Bone marrow hypocellularity
Core phenotype: retinopathy	Bilateral exudative retinopathy is a defining RS feature and can be the presenting manifestation	Retinopathy in all patients with available data; median onset 1.1 years, typically 6-18 months; severe visual loss common; glaucoma in 3 cases (karremann2020reveszsyndromerevisited pages 1-2, karremann2020reveszsyndromerevisited pages 7-8, tomcikova2018whyisit pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)	RS-specific systematic review + case reports	HPO: HP:0000555 Exudative retinopathy, HP:0011003 Retinal detachment, HP:0000501 Glaucoma; UBERON: retina
Core phenotype: intracranial abnormalities	Intracranial calcifications and cerebellar hypoplasia are common neurologic hallmarks; neurodevelopmental delay is frequent but variable	Intracranial calcifications 85%; cerebellar hypoplasia 76%; neurodevelopmental delay/mental retardation 71%; seizures about 20%; intracranial hemorrhage in 3 cases (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 8-9)	RS-specific systematic review + review	HPO: HP:0002521 Cerebral calcification, HP:0001321 Cerebellar hypoplasia, HP:0001263 Developmental delay, HP:0001250 Seizure
Other phenotype features	Classical dyskeratosis congenita mucocutaneous triad is less consistently expressed in RS, likely because of early severe course; growth restriction and fine/sparse hair are common	Only 2 RS cases had complete classic DKC triad in the 2020 review; growth retardation frequent qualitatively (karremann2020reveszsyndromerevisited pages 8-9, rolles2024inheritedtelomerebiology pages 8-9)	RS-specific review	HPO: HP:0001510 Growth delay, HP:0002219 Sparse hair, HP:0001597 Aplasia/hypoplasia of the skin pigmentation pattern
Mechanism	Germline TINF2 mutation disrupts TIN2, a central shelterin component linking TRF1/TRF2 with TPP1/POT1, leading to defective telomere protection/regulation, accelerated telomere shortening, stem-cell replicative exhaustion, and multisystem degeneration. Specific interaction defects vary by variant class	TIN2 mutants cluster in DC hotspot; truncation mutant severely impaired TRF1 interaction; TIN2L/TRF2 and TIN2L/TRF1 interactions are altered by DC-cluster mutations; TINF2 consequences considered multifactorial in broader TBD reviews (nelson2018thecterminalextension pages 1-3, sasa2012threenoveltruncating pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10, rolles2024inheritedtelomerebiology pages 2-4)	Biochemical/in vitro + human genetics + broader TBD review	GO:0000784 nuclear chromosome telomeric region, GO:0032200 telomere organization, GO:0003691 double-stranded telomeric DNA binding, GO:0090398 cellular senescence
Cell and tissue vulnerability	High-turnover stem-cell compartments are most vulnerable; pathology extends beyond blood to retina/CNS and other organs. Tissue-specific shortening may be most severe outside donor-derived hematopoiesis	Broader TBD reviews emphasize HSCs, immune cells, intestinal cells, liver, lung, skin; autopsy in TINF2-DC showed shortest telomeres in lung, liver, kidney and age-appropriate donor hematopoietic tissue after transplant (rolles2024inheritedtelomerebiology pages 2-4, roake2021tissuespecifictelomereshortening pages 1-2)	Broader TBD review + TINF2 human pathology case	CL: hematopoietic stem cell, lymphocyte; UBERON: bone marrow, retina, cerebellum, brain, liver, lung, kidney
Diagnostic workflow	Best-supported workup is clinical recognition of RS features plus telomere testing and germline sequencing of TINF2/TBD genes; flow-FISH is the current clinical standard for functional screening	Age-adjusted lymphocyte telomere length <1st percentile is the commonly used threshold; WES/WGS/panel sequencing recommended after short TL or strong suspicion; chromosome breakage testing is recommended to exclude Fanconi anemia (rolles2024inheritedtelomerebiology pages 8-9, rolles2024inheritedtelomerebiology pages 12-14, rolles2024inheritedtelomerebiology pages 10-12, NCT06817590 chunk 1)	Broader TBD review/guidance, applicable to RS	HPO terms above; LOINC assay for telomere length by flow-FISH; SO/ClinVar variant classification
Differential diagnosis	Main differentials are other TBDs and inherited bone marrow failure disorders, especially Hoyeraal-Hreidarsson syndrome, Coats plus syndrome, and Fanconi anemia	Coats plus may show exudative retinopathy but not necessarily short telomeres; Fanconi anemia exclusion by mitomycin C/DEB testing is recommended in transplant diagnostic pathways (rolles2024inheritedtelomerebiology pages 8-9, rolles2024inheritedtelomerebiology pages 12-14, NCT01659606 chunk 1)	RS-specific/broader TBD reviews + trial eligibility criteria	MONDO/HPO mappings for Hoyeraal-Hreidarsson syndrome, Coats plus syndrome, Fanconi anemia
Prognosis	Prognosis is poor in RS, with death typically in childhood, although transplant may improve hematologic survival in some patients	Kaplan-Meier median survival 6.5 years (95% CI 3.6-9.4); no survival beyond 12 years in 2020 review (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)	RS-specific systematic review	NCIT prognosis annotation; HPO complication terms
Treatment: hematopoietic transplant	Allogeneic stem-cell transplantation is the only potentially curative therapy for marrow failure, but toxicity is a major concern; reduced-intensity, radiation/alkylator-sparing approaches are preferred in TBDs	In RS review, SCT in 8 children; 4 alive at last follow-up after median 22 months; deaths from pulmonary failure reported post-SCT. Broader TBD data note 10-year post-allo-SCT survival about 23% and benefit of non-myeloablative/radiation-avoiding protocols (karremann2020reveszsyndromerevisited pages 1-2, karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 14-15)	RS-specific review + broader TBD extrapolation	NCIT: Hematopoietic Stem Cell Transplantation; NCIT: Reduced-Intensity Conditioning Regimen
Treatment: ophthalmic interventions	Vision-preserving therapy is disease-modifying for the eye but evidence is case-based; laser photocoagulation appears most supported, with anti-VEGF and surgery used in selected eyes	Reported interventions include photocoagulation, intraocular bevacizumab, retinocryopexy, vitrectomy, enucleation; one mosaic TINF2 RS case retained VA 0.9 in treated eye at age 7 after photocoagulation (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 4-7, tomcikova2018whyisit pages 1-2)	RS-specific case reports/review	NCIT: Laser Photocoagulation; NCIT: Bevacizumab; NCIT: Vitrectomy; NCIT: Enucleation
Supportive management	Multidisciplinary surveillance is essential because complications extend across hematologic, ophthalmologic, pulmonary, hepatic, neurologic, mucocutaneous, and cancer domains	No RS-specific formal guideline retrieved; 2022-2024 TBD reviews/guidelines recommend surveillance, specialized-center care, and family counseling (savage2022dyskeratosiscongenitaand pages 5-6, rolles2024inheritedtelomerebiology pages 14-15, NCT04959188 chunk 1)	Broader TBD extrapolation	NCIT care pathway terms; HPO surveillance-linked phenotypes
Pharmacotherapy / experimental systemic therapy	No RS-specific drug proven effective. Broader TBD evidence supports androgen responsiveness in some patients and emerging nucleotide/telomerase-directed strategies	Broader TBD: danazol hematologic response 50-100% short-term; 11/12 gained telomere length with mean +386 bp after 24 months in one study summarized in review; applicability to RS is unproven (rolles2024inheritedtelomerebiology pages 14-15, carvalho2022recentadvancesin pages 7-9, savage2022dyskeratosiscongenitaand pages 5-6)	Broader TBD extrapolation	CHEBI/DrugBank: danazol, oxymetholone, deoxycytidine, thymidine
Current RS-inclusive trials	RS is explicitly included in current TBD clinical trial frameworks rather than having RS-only trials	NCT01659606 active-not-recruiting phase 2 radiation- and alkylator-free HCT, estimated n=40, explicitly includes Revesz syndrome; NCT06817590 recruiting phase 1 oral deoxycytidine + deoxythymidine, estimated n=36, condition list explicitly includes Revesz syndrome; NCT04959188 completed needs-assessment study, n=53, included DC/TBD patients/caregivers (NCT01659606 chunk 1, NCT01659606 chunk 2, NCT06817590 chunk 1, NCT06817590 chunk 2, NCT04959188 chunk 1)	Trial registry evidence	NCIT: Clinical Trial; NCIT: Alemtuzumab/Fludarabine conditioning; CHEBI: deoxycytidine, thymidine
Model organisms / cellular models	No RS-specific animal model was directly retrieved, but TINF2/TBD mechanistic modeling exists in mouse and pluripotent stem-cell systems	TIN2 biochemical cell models show altered shelterin interactions; iPSC DC models recapitulate telomere maintenance defects and loss of self-renewal; a cited mouse study found a DC-associated TINF2 mutation causes telomerase-independent telomere shortening (nelson2018thecterminalextension pages 1-3, batista2011telomereshorteningand pages 1-3, nelson2018thecterminalextension pages 30-33)	In vitro/cellular + cited mouse-model evidence	MGI mouse model annotation; Cellosaurus/iPSC model tags; GO telomere maintenance
Environmental / modifier factors	No RS-specific environmental or protective factors were identified. In broader telomere disease literature, smoking, alcohol, viral infections, radiation, and pulmonary-toxic drugs may worsen organ phenotypes or treatment toxicity	Qualitative only; no RS-specific gene-environment study retrieved (carvalho2022recentadvancesin pages 7-9, rolles2024inheritedtelomerebiology pages 12-14)	Broader TBD extrapolation	CHEBI exposure annotations; evidence-gap flag
Explicit evidence gaps	Major RS evidence gaps remain: prevalence/incidence, penetrance, founder effects, carrier frequency, modifier genes, protective factors, epigenetics, transcriptomics/proteomics/metabolomics, QoL metrics, standardized diagnostic criteria, and controlled treatment-response data	No robust RS-specific 2023-2024 cohort superseding the 2020 review was retrieved; most modern data are TBD-wide extrapolations (karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9, savage2022dyskeratosiscongenitaand pages 5-6)	Evidence-gap synthesis	Evidence code tags for "not available" / "broader TBD extrapolation only"

Table: This table condenses the strongest retrieved evidence for Revesz syndrome across identifiers, genetics, phenotype, mechanism, diagnosis, prognosis, treatment, trials, and evidence gaps. It distinguishes Revesz-specific findings from broader telomere biology disorder extrapolations for knowledge-base use.

1. Disease information

Definition

RS is an ultra-rare, severe pediatric variant within the dyskeratosis congenita/telomere biology disorder spectrum. Its defining clinical combination is bilateral exudative retinopathy, early progressive marrow failure, and CNS abnormalities—particularly intracranial calcification and cerebellar hypoplasia. Unlike classic dyskeratosis congenita, the complete mucocutaneous triad of nail dystrophy, reticular pigmentation, and oral leukoplakia is uncommon at presentation, probably because RS begins and progresses before all age-dependent features can develop. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

A concise direct quotation from the 2020 abstract is: “RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients.” (karremann2020reveszsyndromerevisited pages 1-2)

Identifiers and synonyms

MONDO: MONDO:0009990.
OMIM: #268130.
MeSH: no uniquely retrieved RS descriptor; use the broader Dyskeratosis Congenita, D019871, with an RS subtype annotation.
ClinicalTrials.gov/MeSH supplementary concept: “Revesz Debuse syndrome,” concept C538371.
ICD-10/ICD-11: no specific RS code was identified. Coding generally falls under congenital marrow-failure, dyskeratosis congenita, retinal, and neurologic manifestations, depending on jurisdiction.
Synonyms: Revesz syndrome; Revesz–Debuse syndrome; Revesz type dyskeratosis congenita; TINF2-associated Revesz syndrome; TINF2-associated dyskeratosis congenita with bilateral exudative retinopathy and intracranial calcification. (OpenTargets Search: Revesz syndrome-TINF2, karremann2020reveszsyndromerevisited pages 1-2, NCT06817590 chunk 2)

Open Targets links MONDO:0009990 specifically to TINF2/ENSG00000092330, supported by five association evidence records and literature including PMID 18252230 and 21477109. (OpenTargets Search: Revesz syndrome-TINF2)

2. Etiology

Causal factor

RS is primarily a germline Mendelian disorder caused by heterozygous pathogenic variants in TINF2, encoding TIN2, a central shelterin-complex protein. The causal lesion is constitutional rather than infectious, toxic, or acquired. Most genetically characterized RS cases have apparently de novo variants, although TINF2-related TBDs can be transmitted as autosomal-dominant disorders. (karremann2020reveszsyndromerevisited pages 7-8, sasa2012threenoveltruncating pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

Genetic risk factors

The dominant risk factor is a pathogenic TINF2 variant, especially within the narrow exon-6 dyskeratosis-congenita hotspot. Variants reported in RS or overlapping RS/Hoyeraal–Hreidarsson phenotypes include:

NM_001099274.1:c.845G>A, p.Arg282His, the recurrent hotspot;
c.838A>T, p.Lys280Ter;
c.839delA, p.Lys280ArgfsTer36, a truncating RS-associated allele;
c.865C>T, p.Pro289Ser, reported in mosaic form in one RS case.

The historical variant series showed p.Arg282His in 12 DC probands, two DC/RS probands, one DC/HH/RS proband, and two HH probands, illustrating that a TINF2 genotype does not map uniquely to one syndromic label. (tomcikova2018whyisit pages 1-2, sasa2012threenoveltruncating pages 1-3, sasa2012threenoveltruncating pages 3-4)

Environmental, protective, and gene–environment factors

No environmental exposure is known to cause RS, and no validated genetic or environmental protective factor, modifier allele, founder effect, diet, or lifestyle intervention has been demonstrated specifically in RS. Broader TBD literature suggests that smoking, alcohol, viral infection, ionizing radiation, and pulmonary-toxic or DNA-damaging drugs may aggravate organ injury or treatment toxicity, but this is not RS-specific evidence. (rolles2024inheritedtelomerebiology pages 12-14, carvalho2022recentadvancesin pages 7-9)

3. Phenotypes

The frequencies below derive principally from 18 published children and are vulnerable to case-report ascertainment and incomplete reporting.

Bone-marrow failure/pancytopenia: severe, progressive laboratory and clinical phenotype; effectively universal in the reviewed RS series. It occurred from 6 months to 6 years, with median onset 1.5 years; all affected children had developed it by age six. Consequences include infection, bleeding, anemia, transfusion dependence, and transplant need. Suggested HPO: HP:0001876 Pancytopenia, HP:0005528 Bone marrow hypocellularity, HP:0001903 Anemia, HP:0001873 Thrombocytopenia, HP:0001875 Neutropenia. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)
Bilateral exudative retinopathy: defining, severe, and progressive; present in all 15 children for whom retinal data were available. Median onset was 1.1 years (95% CI 0.7–1.5), usually at 6–18 months. It can progress to proliferative vitreoretinopathy, retinal detachment, neovascular glaucoma, blindness, and enucleation. Suggested HPO: HP:0000555 Exudative retinopathy, HP:0011003 Retinal detachment, HP:0000501 Glaucoma, HP:0000510 Blindness. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 7-8, tomcikova2018whyisit pages 1-2)
Intracranial calcification: imaging sign reported in approximately 85%. Suggested HPO: HP:0002514/HP:0002521 intracranial/cerebral calcification; terminology should be verified against the current HPO release. (karremann2020reveszsyndromerevisited pages 7-8)
Cerebellar hypoplasia and ataxia: cerebellar hypoplasia in approximately 76%; generally congenital/developmental and non-reversible. Suggested HPO: HP:0001321 Cerebellar hypoplasia, HP:0001251 Ataxia. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 8-9)
Developmental delay/intellectual impairment: approximately 71%, usually recognized in infancy or early childhood, with variable severity. Suggested HPO: HP:0001263 Global developmental delay, HP:0001249 Intellectual disability. (karremann2020reveszsyndromerevisited pages 7-8)
Seizures: estimated cumulative frequency approximately 20%, exclusively beginning in early childhood in the reviewed cases. Suggested HPO: HP:0001250 Seizure. (karremann2020reveszsyndromerevisited pages 1-2)
Intracranial hemorrhage: three reviewed patients; potentially catastrophic. Suggested HPO: HP:0002170 Intracranial hemorrhage. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 7-8)
Growth restriction: intrauterine or postnatal, qualitatively common. Suggested HPO: HP:0001511 Intrauterine growth retardation, HP:0001510 Growth delay, HP:0004322 Short stature. (sasa2012threenoveltruncating pages 1-3, rolles2024inheritedtelomerebiology pages 8-9)
Mucocutaneous findings: nail dystrophy was the most frequent element, with variable reticular pigmentation, oral leukoplakia, and fine/sparse hair. Only two children had the full classic DC triad. Suggested HPO: HP:0001597 Abnormality of the nail, HP:0009713 Nail dystrophy, HP:0001000 Abnormality of skin pigmentation, HP:0002745 Oral leukoplakia, HP:0002219 Sparse hair. (karremann2020reveszsyndromerevisited pages 8-9, rolles2024inheritedtelomerebiology pages 8-9)

No RS-specific EQ-5D, SF-36, PROMIS, or other standardized quality-of-life measurements were identified. Nevertheless, blindness, developmental disability, transfusion dependence, infection risk, and repeated hospitalization imply profound effects on mobility, education, communication, independence, and family burden. A completed NIH needs-assessment study enrolled 53 DC/TBD patients and caregivers, but it was not RS-specific. (NCT04959188 chunk 1)

4. Genetic and molecular information

Gene and protein

Gene: TINF2, TERF1 interacting nuclear factor 2.
Ensembl: ENSG00000092330.
Protein: TIN2, a shelterin component linking TRF1/TRF2 to TPP1/POT1.
Inheritance: autosomal dominant, usually de novo in severe pediatric TINF2 disease.
Origin: constitutional/germline; mosaicism has occasionally been reported. These are not characteristically somatic cancer-driver lesions. (OpenTargets Search: Revesz syndrome-TINF2, nelson2018thecterminalextension pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

Variant classes and consequences

Both missense and truncating alleles occur. Stable truncated TIN2 protein was demonstrated in patient-derived lymphoblastoid cells, arguing against a simple null/haploinsufficiency model for all alleles. A truncation markedly impaired TIN2–TRF1 interaction, whereas common p.Arg282His had a smaller effect on that particular interaction. TINF2 pathogenesis is therefore best annotated as multifactorial altered-function/dominant dysfunction, with variant-dependent effects on shelterin organization, telomerase regulation, telomere cohesion, and end protection; a universal dominant-negative mechanism has not been proven. (sasa2012threenoveltruncating pages 1-3, nelson2018thecterminalextension pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

The biochemical abstract states: “TIN2 is central to the shelterin complex, linking the telomeric proteins TRF1 and TRF2 with TPP1/POT1.” It further concludes that TIN2 isoforms are functionally distinguishable and that shelterin composition may be altered in patients with TINF2 mutations. (nelson2018thecterminalextension pages 1-3)

Population allele frequencies were not available in the retrieved evidence. Given severe early-onset disease and frequent de novo occurrence, established pathogenic RS alleles are expected to be absent or extremely rare in population databases, but each HGVS allele must be checked directly in current gnomAD and ClinVar before database ingestion. No recurrent RS-associated chromosomal rearrangement, aneuploidy, or large structural variant was identified.

Modifiers and epigenetics

No validated RS modifier gene or disease-specific epigenetic signature is known. Somatic reversion has been reported in TINF2-related TBD more broadly and may obscure blood-based variant detection, occasionally making fibroblast DNA testing necessary. This has not been established as a protective mechanism in RS. (savage2022dyskeratosiscongenitaand pages 8-10)

5. Environmental information

RS is not infectious and has no zoonotic or contagious component. No toxin, pollutant, occupational exposure, smoking pattern, diet, exercise level, or alcohol exposure is established as etiologic. Because telomere-deficient tissues have limited regenerative reserve, avoidance of tobacco, excessive alcohol, unnecessary radiation, and organ-toxic medications is biologically and clinically prudent under general TBD management, but evidence is indirect for RS. (rolles2024inheritedtelomerebiology pages 12-14, carvalho2022recentadvancesin pages 7-9)

6. Mechanism and pathophysiology

Ordered causal chain

A heterozygous germline TINF2 hotspot or truncating variant leads to altered TIN2 structure or protein interactions.
Altered TIN2 leads to defective integration/regulation of the TRF1–TIN2–TRF2–TPP1/POT1 shelterin network and telomerase recruitment; the exact defect is variant-dependent.
Shelterin/telomerase dysregulation leads to exceptionally rapid telomere attrition and/or defective telomere capping; telomerase-independent shortening has been demonstrated in a Tinf2-mutant mouse model.
Critically short or uncapped telomeres lead to DNA-damage signaling, chromosome instability, senescence, apoptosis, and loss of self-renewal.
Stem/progenitor-cell exhaustion leads directly to failure of high-turnover tissues—most demonstrably hematopoietic stem/progenitor cells—resulting in hypocellular marrow and pancytopenia.
Retinal branch: telomere-associated vascular/endothelial or supporting-cell dysfunction is inferred to lead to peripheral capillary nonperfusion, leakage, neovascularization, exudation, retinal detachment, glaucoma, and blindness; this cell-level sequence remains incompletely demonstrated in RS.
Neurodevelopmental branch: developmental telomere dysfunction is inferred to disrupt cerebellar and cerebral growth and microvascular integrity, resulting in cerebellar hypoplasia, calcification, white-matter abnormalities, developmental delay, seizures, and occasional hemorrhage.
Systemic branch: limited tissue regenerative capacity leads to mucocutaneous degeneration, growth restriction, infection susceptibility, and later pulmonary/hepatic complications, compounded in some patients by treatment toxicity. (karremann2020reveszsyndromerevisited pages 9-11, sasa2012threenoveltruncating pages 1-3, nelson2018thecterminalextension pages 1-3, nelson2018thecterminalextension pages 30-33, rolles2024inheritedtelomerebiology pages 2-4, rolles2024inheritedtelomerebiology pages 10-12)

Processes and ontology suggestions

Relevant GO concepts include telomere maintenance (GO:0000723), telomere organization (GO:0032200), protein localization to chromosome, telomeric region, DNA-damage response, cellular senescence (GO:0090398), stem-cell population maintenance (GO:0019827), and apoptotic process (GO:0006915). Relevant cellular components include nuclear chromosome telomeric region (GO:0000784) and shelterin complex. Candidate CL annotations include hematopoietic stem cell, hematopoietic progenitor cell, retinal endothelial cell, retinal pigment epithelial cell, photoreceptor cell, neuron, cerebellar granule cell, and glial cell; only hematopoietic stem-cell involvement is strongly demonstrated, while the exact retinal/CNS target populations remain uncertain.

No RS-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or integrated multi-omics dataset was identified. DC iPSCs recapitulate telomere-maintenance defects and eventual loss of self-renewal, but the retrieved iPSC study did not specifically model RS/TINF2. (batista2011telomereshorteningand pages 1-3)

7. Anatomical structures affected

Primary sites are:

Bone marrow/hematopoietic system—hematopoietic stem and progenitor compartments; UBERON: bone marrow.
Both retinas and retinal vasculature—bilateral by definition; UBERON: retina, retinal blood vessel, vitreous body.
Brain, especially cerebellum and periventricular white matter; UBERON: brain, cerebellum, cerebral white matter, ventricular system.
Skin, nails, oral mucosa, and hair follicles.
Secondary or later TBD-associated involvement may include lung, liver, gastrointestinal tract, kidney, and immune system.

A TINF2-DC autopsy—not a classic RS case—showed donor-derived hematopoietic tissue with age-appropriate telomeres but severe shortening in native tissues, especially lung, liver, and kidney, supporting tissue-specific vulnerability beyond marrow. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 4-7, rolles2024inheritedtelomerebiology pages 8-9, roake2021tissuespecifictelomereshortening pages 1-2)

At the subcellular level, the principal compartment is the nucleus, particularly telomeric chromatin and shelterin at chromosome ends.

8. Temporal development

RS is congenital in genetic origin and usually manifests during infancy. Retinopathy generally appears at 6–18 months, often before or alongside hematologic disease. Marrow failure usually becomes apparent in the second year and was present by age six in all reviewed patients. Neurodevelopmental abnormalities may be evident prenatally or in early infancy; seizures, when present, begin in early childhood. The course is chronic, progressive, and lifelong, without documented spontaneous remission. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

There is no validated stage system. A practical clinical sequence is: congenital growth/CNS abnormality → infantile retinopathy → early cytopenias/marrow failure → progressive visual and neurologic disability → severe infections, bleeding, pulmonary complications, or transplant-related morbidity. The first 1–2 years constitute a critical window for retinal surveillance and hematologic diagnosis.

9. Inheritance and population

RS is autosomal dominant at the molecular level but is most often caused by a de novo heterozygous TINF2 variant. Recurrence risk is low but not zero when parents test negative because parental germline mosaicism cannot be excluded. An affected individual would theoretically have a 50% transmission risk, although severe childhood mortality limits observed vertical transmission. Familial TINF2 TBD shows variable expressivity; the penetrance of specific RS alleles has not been quantified. (karremann2020reveszsyndromerevisited pages 7-8, savage2022dyskeratosiscongenitaand pages 5-6, savage2022dyskeratosiscongenitaand pages 8-10)

Telomere-mediated genetic anticipation is recognized across TBDs, but direct multigenerational anticipation data for RS are lacking. No founder allele, population enrichment, consanguinity effect, or carrier frequency has been demonstrated. In the 18-child review there were 11 boys and seven girls; this small difference did not establish a biologically meaningful sex bias. No prevalence or incidence per 100,000 can be calculated reliably. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 10-12)

10. Diagnostics

Recommended workflow

Recognize the combination of infantile bilateral exudative retinopathy, unexplained cytopenia/hypocellular marrow, intracranial calcification/cerebellar hypoplasia, growth restriction, or DC stigmata.
Obtain CBC with differential, reticulocyte count, marrow aspirate/biopsy with morphology and cytogenetics, and infection/immunologic evaluation.
Perform complete dilated retinal examination, wide-field imaging and fluorescein angiography where feasible; assess retinal nonperfusion, leakage, exudation, neovascularization, detachment, and glaucoma.
Obtain noncontrast head CT for calcification and MRI for cerebellar, callosal, white-matter, hemorrhagic, and cystic abnormalities.
Measure leukocyte telomere length by flow-FISH, preferably lymphocyte and granulocyte subsets. Lymphocyte length below the age-adjusted first percentile is the standard “very short” threshold; seven measured RS patients were below this threshold. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 8-9)
Sequence TINF2, including exon 6, using a comprehensive TBD/inherited-marrow-failure panel. If unrevealing, use WES or WGS with copy-number analysis and consider non-blood DNA if somatic reversion/mosaicism is suspected. (rolles2024inheritedtelomerebiology pages 10-12, savage2022dyskeratosiscongenitaand pages 5-6, savage2022dyskeratosiscongenitaand pages 8-10)
Perform mitomycin-C or diepoxybutane chromosome-breakage testing when Fanconi anemia remains possible. CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not first-line RS tests unless another diagnosis is suspected. (rolles2024inheritedtelomerebiology pages 12-14, NCT01659606 chunk 1)

A reported RS child had telomere lengths of 2.47–2.48 kb, below the first percentile, and TINF2 c.845G>A/p.Arg282His. (karremann2020reveszsyndromerevisited pages 4-7)

Differential diagnosis

Coats plus/CRMCC, usually CTC1, STN1 or POT1 related: retinal telangiectasia, calcifications, white-matter disease, cysts, GI bleeding, and bone disease; telomeres may be normal.
Hoyeraal–Hreidarsson syndrome: cerebellar hypoplasia, growth restriction, immunodeficiency, microcephaly and severe marrow failure, often DKC1 or biallelic RTEL1 related; exudative retinopathy is less defining.
Classic DC/other TBDs: mucocutaneous triad and marrow failure without the characteristic RS retinal/CNS combination.
Fanconi anemia: congenital anomalies and marrow failure with positive chromosome-breakage testing.
Isolated Coats disease/familial exudative vitreoretinopathy: retinal disease without very short telomeres or systemic marrow failure.
Congenital infection and metabolic causes of intracranial calcification should be excluded based on context. (rolles2024inheritedtelomerebiology pages 8-9, NCT01659606 chunk 1)

No universally accepted RS-only diagnostic criteria exist; diagnosis is syndromic plus molecular/functional confirmation.

11. Outcome and prognosis

In the 18-child review, Kaplan–Meier median survival was 6.5 years (95% CI 3.6–9.4), and no reported patient survived beyond 12 years. These historical estimates are based on very small, heterogeneous case reports and may not reflect contemporary transplant and ophthalmic care. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

Major morbidity includes blindness, developmental disability, ataxia, seizures, recurrent infection, bleeding, transfusion dependence, transplant toxicity, and pulmonary failure. Three patients had intracranial hemorrhage. In a 2023 childhood DC natural-history cohort, the RS patient developed cerebral calcifications and retinopathy progressing to blindness and later died from septic shock after dental/gum infection, illustrating combined visual and immune/hematologic morbidity. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 7-8)

Poor prognostic markers plausibly include very early marrow failure, severe retinal disease, profound telomere shortening, pre-existing pulmonary/hepatic injury, infection, hemorrhage, and inability to undergo successful transplantation. No validated RS prognostic score or biomarker beyond phenotype, organ status, blood counts, and telomere length exists.

12. Treatment

Hematologic treatment

Allogeneic hematopoietic-cell transplantation (HCT) is the only established potentially curative treatment for marrow failure, but it does not correct retinal, neurologic, pulmonary, hepatic, or other native-tissue telomere pathology. Eight of 18 reviewed RS children underwent transplantation; four were alive at last follow-up after a median of 22 months. Two reported late deaths were from pulmonary failure at two and 4.5 years after HCT. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 1-2)

Reduced-intensity, radiation-avoiding conditioning is preferred because TBD tissues are unusually sensitive to DNA-damaging chemotherapy and radiation. Four RS cases receiving fludarabine/cyclophosphamide/antithymocyte-globulin conditioning had limited acute toxicity, but long-term evidence remains weak. In broader TBD cohorts, 10-year post-HCT survival was about 23%, with progressive pulmonary fibrosis an important late complication. (karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 14-15)

The active-not-recruiting phase-2 NCT01659606 explicitly includes RS and evaluates an alkylator- and radiation-free regimen of alemtuzumab plus fludarabine, followed by cyclosporine or tacrolimus and mycophenolate prophylaxis; target enrollment is 40. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01659606. (NCT01659606 chunk 1, NCT01659606 chunk 2)

Suggested NCIT concepts: Hematopoietic Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Reduced-Intensity Conditioning, Fludarabine, Alemtuzumab, Cyclophosphamide, and Antithymocyte Globulin.

Ophthalmic treatment

Urgent retinal treatment is warranted before irreversible detachment or glaucoma. Reported approaches include laser photocoagulation of avascular retina, cryotherapy, intravitreal bevacizumab, vitrectomy, and—when a painful blind eye develops—enucleation. Evidence consists of case reports, not comparative trials. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 4-7, tomcikova2018whyisit pages 1-2)

One child with mosaic TINF2 p.Pro289Ser had the left eye enucleated for neovascular glaucoma, while photocoagulation of the right ischemic retina preserved reported visual acuity of 0.9 at age seven. This supports early retinal examination in every young child with unexplained aplastic anemia. (tomcikova2018whyisit pages 1-2)

Suggested NCIT concepts: Laser Photocoagulation, Cryotherapy, Bevacizumab, Intravitreal Injection, Vitrectomy, and Enucleation.

Pharmacotherapy and supportive care

Transfusions, infection prophylaxis/treatment, dental care, nutritional support, developmental therapies, low-vision services, seizure treatment, and physical/occupational/speech therapy should be individualized. Standard immunosuppressive therapy for acquired aplastic anemia generally has little benefit in constitutional TBD marrow failure. (rolles2024inheritedtelomerebiology pages 10-12, carvalho2022recentadvancesin pages 7-9)

Oral androgens such as danazol or oxymetholone can improve counts in some TBD patients, but there are no RS-specific response data. A 2024 review reported short-term hematologic responses in approximately 50–100% of heterogeneous TBD patients receiving danazol; in one underlying study, 11/12 gained telomere length (mean +386 bp) and 83% had a hematologic response at 24 months. Hepatotoxicity, virilization, lipid changes, and clonal evolution require monitoring. These figures must not be interpreted as RS response rates. (rolles2024inheritedtelomerebiology pages 12-14, rolles2024inheritedtelomerebiology pages 14-15)

Emerging therapy

NCT06817590, a phase-1 Boston Children’s Hospital study first posted 10 February 2025, explicitly includes RS. It evaluates oral deoxycytidine plus deoxythymidine three times daily for 24 weeks in 36 estimated participants aged 1–70, based on 2023 evidence that thymidine-nucleotide metabolism controls human telomere length (PMID 36959362). Outcomes include safety, blood counts, telomere length, marrow cellularity, clonal hematopoiesis, and pulmonary function. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06817590. This is experimental and has no efficacy result yet. (NCT06817590 chunk 1, NCT06817590 chunk 2)

PAPD5 inhibition, engineered telomerase RNA, gene editing, and telomerase gene therapy remain preclinical or early translational TBD approaches. No approved RS gene, RNA, or cell therapy exists. (rolles2024inheritedtelomerebiology pages 14-15)

13. Prevention

Primary prevention by lifestyle change is impossible because RS is genetic. Reproductive options after identification of a familial pathogenic variant include genetic counseling, prenatal diagnosis, and preimplantation genetic testing. Parental testing should include discussion of possible germline mosaicism.

Secondary prevention centers on early detection: cascade testing, CBC surveillance, telomere testing where indicated, immediate retinal examination in infants with cytopenia or suspected TBD, and neuroimaging when CNS features are present. Population newborn screening is not available.

Tertiary prevention includes early laser treatment of avascular retina, prompt infection management, meticulous dental care, matched-donor screening, avoidance of affected related donors, reduced-toxicity HCT conditioning, sun protection, smoking avoidance, minimized diagnostic/therapeutic radiation, and surveillance for pulmonary, hepatic, marrow-clonal, mucosal, and malignant complications. General vaccines should follow expert guidance tailored to immune status and transplant timing; there is no RS-specific vaccine. (NCT01659606 chunk 1, savage2022dyskeratosiscongenitaand pages 5-6, carvalho2022recentadvancesin pages 7-9)

14. Other species and natural disease

No naturally occurring veterinary syndrome equivalent to human RS was identified in companion animals, livestock, or wildlife. RS has no zoonotic potential and cannot be transmitted between species. TINF2 orthologues are evolutionarily conserved in vertebrates, preserving the central shelterin role, but orthologue identifiers should be retrieved directly from current NCBI Gene/Alliance records before database deposition.

15. Model organisms and experimental systems

Mouse: a knock-in model carrying a DC-associated Tinf2 mutation demonstrated telomerase-independent telomere shortening, supporting a direct TIN2 role beyond simply reducing telomerase activity. It models the molecular lesion but has not been shown here to reproduce the complete human RS combination of retinopathy, intracranial calcification, and infantile marrow failure. (nelson2018thecterminalextension pages 30-33)
Human patient-derived cells: lymphoblastoid lines expressing truncating TIN2 demonstrated stable mutant protein and impaired TRF1 interaction. These are useful for shelterin biochemistry but do not reproduce tissue-level RS. (sasa2012threenoveltruncating pages 1-3)
Engineered cell systems: overexpression and CRISPR studies distinguish TIN2S and TIN2L interactions with TRF1/TRF2 and their permissiveness for telomere elongation. (nelson2018thecterminalextension pages 1-3, nelson2018thecterminalextension pages 8-10)
DC iPSCs: patient-derived iPSCs reproduce biochemical telomere defects and loss of self-renewal, making them a platform for therapeutic screening; however, the retrieved study modeled TERT, DKC1, and TCAB1 disease rather than RS-specific TINF2 alleles. (batista2011telomereshorteningand pages 1-3)

No validated RS retinal organoid, cerebral organoid, zebrafish, Drosophila, rat, or naturally occurring animal model was identified.

Recent developments and expert assessment

The major 2023–2024 advance is not a new RS natural-history cohort but refinement of the broader TBD framework. The July 2024 review by Rolles et al. reaffirmed RS as an early severe pediatric TBD with telomeres “considerably below the 1% percentile,” endorsed lymphocyte flow-FISH followed by germline sequencing, and emphasized reduced-intensity/radiation-avoiding HCT. DOI: 10.1159/000540109. (rolles2024inheritedtelomerebiology pages 8-9, rolles2024inheritedtelomerebiology pages 14-15)

The 2023 thymidine-metabolism study (PMID 36959362; DOI: 10.1038/s41588-023-01339-5) supplied the mechanistic basis for the subsequent RS-inclusive dC/dT phase-1 trial. This represents a transition from supportive/transplant care toward attempts to manipulate telomere substrate metabolism, although clinical benefit remains unproven. (NCT06817590 chunk 1, NCT06817590 chunk 2)

The principal expert conclusion is that RS should be managed as a multisystem developmental and degenerative disorder, not merely aplastic anemia. HCT can replace hematopoiesis but cannot repair the retina, brain, lung, or liver; successful care therefore requires coordinated hematology/transplantation, ophthalmology, neurology, genetics, pulmonology, hepatology, dentistry, rehabilitation, and psychosocial support. (karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 14-15, NCT04959188 chunk 1)

Priority knowledge gaps

Reliable prevalence, incidence, penetrance, allele-specific natural history, population frequencies, germline-mosaic recurrence risk, modifier genes, protective factors, quantitative quality of life, retinal cellular mechanism, RS-specific omics, and controlled treatment outcomes are unavailable. Published percentages arise from fewer than 20 historical patients and should be stored with small-sample and ascertainment-bias qualifiers. No 2023–2024 RS-specific cohort, randomized trial, approved targeted therapy, or validated prognostic model was identified. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)

References

(karremann2020reveszsyndromerevisited pages 8-9): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.
(karremann2020reveszsyndromerevisited pages 1-2): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.
(rolles2024inheritedtelomerebiology pages 8-9): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.
(karremann2020reveszsyndromerevisited pages 7-8): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.
(OpenTargets Search: Revesz syndrome-TINF2): Open Targets Query (Revesz syndrome-TINF2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(savage2022dyskeratosiscongenitaand pages 8-10): Sharon A. Savage. Dyskeratosis congenita and telomere biology disorders. Hematology. American Society of Hematology. Education Program, 2022 1:637-648, Dec 2022. URL: https://doi.org/10.1182/hematology.2022000394, doi:10.1182/hematology.2022000394. This article has 119 citations.
(rolles2024inheritedtelomerebiology pages 2-4): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.
(sasa2012threenoveltruncating pages 3-4): Ghadir Sasa, Albert Ribes-Zamora, Nya D. Nelson, and Alison A. Bertuch. Three novel truncating tinf2 mutations causing severe dyskeratosis congenita in early childhood. Clinical Genetics, 81:470-478, May 2012. URL: https://doi.org/10.1111/j.1399-0004.2011.01658.x, doi:10.1111/j.1399-0004.2011.01658.x. This article has 118 citations and is from a peer-reviewed journal.
(tomcikova2018whyisit pages 1-2): D. Tomcikova, A. Gerinec, B. Busanyova, M. Gresikova, S. Biskup, and K. Hortnagel. Why is it necessary to examine retina when the patient suffers from aplastic anemia? Bratislavske lekarske listy, 119 5:275-277, Jan 2018. URL: https://doi.org/10.4149/bll_2018_051, doi:10.4149/bll_2018_051. This article has 7 citations.
(karremann2020reveszsyndromerevisited pages 4-7): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.
(karremann2020reveszsyndromerevisited pages 9-11): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.
(nelson2018thecterminalextension pages 1-3): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.
(sasa2012threenoveltruncating pages 1-3): Ghadir Sasa, Albert Ribes-Zamora, Nya D. Nelson, and Alison A. Bertuch. Three novel truncating tinf2 mutations causing severe dyskeratosis congenita in early childhood. Clinical Genetics, 81:470-478, May 2012. URL: https://doi.org/10.1111/j.1399-0004.2011.01658.x, doi:10.1111/j.1399-0004.2011.01658.x. This article has 118 citations and is from a peer-reviewed journal.
(roake2021tissuespecifictelomereshortening pages 1-2): Caitlin M. Roake, Marisa Juntilla, Rajni Agarwal-Hashmi, Steven Artandi, and Christin S. Kuo. Tissue-specific telomere shortening and degenerative changes in a patient with tinf2 mutation and dyskeratosis congenita. Human Pathology: Case Reports, 25:200517, Sep 2021. URL: https://doi.org/10.1016/j.ehpc.2021.200517, doi:10.1016/j.ehpc.2021.200517. This article has 6 citations.
(rolles2024inheritedtelomerebiology pages 12-14): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.
(rolles2024inheritedtelomerebiology pages 10-12): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.
(NCT06817590 chunk 1): Suneet Agarwal. Nucleoside Therapy in Patients With Telomere Biology Disorders. Suneet Agarwal. 2025. ClinicalTrials.gov Identifier: NCT06817590
(NCT01659606 chunk 1): Suneet Agarwal. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita. Boston Children's Hospital. 2012. ClinicalTrials.gov Identifier: NCT01659606
(rolles2024inheritedtelomerebiology pages 14-15): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.
(savage2022dyskeratosiscongenitaand pages 5-6): Sharon A. Savage. Dyskeratosis congenita and telomere biology disorders. Hematology. American Society of Hematology. Education Program, 2022 1:637-648, Dec 2022. URL: https://doi.org/10.1182/hematology.2022000394, doi:10.1182/hematology.2022000394. This article has 119 citations.
(NCT04959188 chunk 1): Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD). National Cancer Institute (NCI). 2021. ClinicalTrials.gov Identifier: NCT04959188
(carvalho2022recentadvancesin pages 7-9): Vinicius S Carvalho, Willian R Gomes, and Rodrigo T Calado. Recent advances in understanding telomere diseases. Faculty Reviews, Oct 2022. URL: https://doi.org/10.12703/r/11-31, doi:10.12703/r/11-31. This article has 24 citations.
(NCT01659606 chunk 2): Suneet Agarwal. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita. Boston Children's Hospital. 2012. ClinicalTrials.gov Identifier: NCT01659606
(NCT06817590 chunk 2): Suneet Agarwal. Nucleoside Therapy in Patients With Telomere Biology Disorders. Suneet Agarwal. 2025. ClinicalTrials.gov Identifier: NCT06817590
(batista2011telomereshorteningand pages 1-3): Luis F. Z. Batista, Matthew F. Pech, Franklin L. Zhong, Ha Nam Nguyen, Kathleen T. Xie, Arthur J. Zaug, Sharon M. Crary, Jinkuk Choi, Vittorio Sebastiano, Athena Cherry, Neelam Giri, Marius Wernig, Blanche P. Alter, Thomas R. Cech, Sharon A. Savage, Renee A. Reijo Pera, and Steven E. Artandi. Telomere shortening and loss of self-renewal in dyskeratosis congenita ips cells. Nature, 474:399-402, May 2011. URL: https://doi.org/10.1038/nature10084, doi:10.1038/nature10084. This article has 316 citations and is from a highest quality peer-reviewed journal.
(nelson2018thecterminalextension pages 30-33): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.
(nelson2018thecterminalextension pages 8-10): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	10
Resolved	10
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	10
On topic	4
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	40
Resolved	39
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	0
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0009990 (5 mentions) - the report calls it "if available"; MONDO calls it Revesz syndrome

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0000784 (GO_0000784) (2 mentions) - replaced by GO:0000781

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Revesz Syndrome: Comprehensive Disease-Characteristics Report

1. Disease information

Definition

Identifiers and synonyms

2. Etiology

Causal factor

Genetic risk factors

Environmental, protective, and gene–environment factors

3. Phenotypes

4. Genetic and molecular information

Gene and protein

Variant classes and consequences

Modifiers and epigenetics

5. Environmental information

6. Mechanism and pathophysiology

Ordered causal chain

Processes and ontology suggestions

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended workflow

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Hematologic treatment

Ophthalmic treatment

Pharmacotherapy and supportive care

Emerging therapy

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Recent developments and expert assessment

Priority knowledge gaps

Artifacts

Reference Validation

Term Validation

Terms the report names something else

Obsolete terms